Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

SUBSCRIBE NOW!

Available in March 1996

New 16th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION
1996

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- USP Monograph Title Additions or Changes
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Cumulative Supplement 11

NOVEMBER 1995

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

CUMULATIVE SUPPLEMENT 11
NOVEMBER 1995

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 15th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 15th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 16th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

The Uruguay Round Agreements Act (URAA), Public Law 103-465, extended the term of patents issued on or after June 8, 1995, from 17 years from date of issue to 20 years from date of filing. Patents in effect on, or based upon applications filed by, June 8, 1995, are entitled to 17 years from date of issue or 20 years from date of filing, whichever is greater. On June 7, 1995, the Patent and Trademark Office (PTO) published a notice in the *Federal Register* (60 FR 30069) that established the method for calculating the patent term expiration date for any patent subject to both the terms of the URAA and the patent term extension provisions at title 35, U.S.C. § 156. FDA published a notice in the *Federal Register* on July 21, 1995, (60 FR 37652) announcing that it would not publish

in this publication patent expiration dates that the NDA applicant submitting the information stated were not calculated in accordance with the PTO method for determining the correct patent expiration date.

Both PTO's determination of the correct relationship between the extension of patents under the URAA and patent term extensions under title 35, U.S.C. § 156, and FDA's refusal to publish patent expiration dates that are not consistent with the PTO determination have been challenged. On October 16, 1995, the U.S. District Court for the Eastern District of Virginia issued an Opinion and Order finding that PTO had misinterpreted the Patent Code, and that PTO's determination of June 7, 1995, is invalid and unenforceable. The court ordered FDA to publish the patent dates it had, by its July 21, 1995, notice, refused to publish. Therefore, because of the court's order, and pending final resolution of appeals from the October 16, 1995, decision, FDA is publishing the patent term expiration dates that NDA applicants have told FDA are not consistent with PTO's June 7, 1995, determination. Because the district court decision may be reversed upon appeal, users of this publication should consult the most recent supplement and are encouraged to confirm that patent information upon which they intend to rely is current.

1.3 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release;transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated

as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.4 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BOOTS PHARMACEUTICALS INC (BOOTS)	KNOLL PHARMACEUTICAL COMPANY SUB BASF CORPORATION (KNOLL PHARM)
BRIAN PHARMACEUTICALS INC (BRIAN)	HYGENICS PHARMACEUTICALS INC (HYGENICS)

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1994) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1994	MAR 1995	JUN 1995	SEP 1995
DRUG PRODUCTS LISTED	9141	9195	9221	9221
SINGLE SOURCE	2178 (23.8%)	2186 (23.8%)	2186 (23.7%)	2168 (23.5%)
MULTISOURCE	6963 (76.2%)	7009 (76.2%)	7035 (76.3%)	7053 (76.5%)
THERAPEUTICALLY EQUIVALENT	6330 (69.2%)	6380 (69.4%)	6399 (69.4%)	6427 (69.7%)
NOT THERAPEUTICALLY EQUIVALENT	453 (5.0%)	453 (4.9%)	452 (4.9%)	444 (4.8%)
EXCEPTIONS[1]	180 (2.0%)	176 (1.9%)	184 (2.0%)	182 (2.0%)
NEW MOLECULAR ENTITIES APPROVED	--	2	10	6
NUMBER OF APPLICANTS	534	541	559	553

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

PRESCRIPTION DRUG PRODUCT LIST
15TH EDITION
RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 11 / JAN'95 - NOV'95

ACARBOSE

TABLET; ORAL
PRECOSE
BAYER — 50MG — N20482 001 SEP 06, 1995
\+ — 100MG — N20482 002 SEP 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
ACEBUTOLOL HCL
AB MYLAN — EQ 200MG BASE — N74288 001 APR 24, 1995
AB — EQ 400MG BASE — N74288 002 APR 24, 1995
AB WATSON LABS — EQ 200MG BASE — N74007 001 OCT 18, 1995
AB — EQ 400MG BASE — N74007 002 OCT 18, 1995
SECTRAL
AB WYETH AYERST — EQ 200MG BASE — N18917 001 DEC 28, 1984
AB + — EQ 400MG BASE — N18917 003 DEC 28, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
AB WEST WARD PHARM — 325MG;50MG;40MG — N89718 001 JUN 12, 1995

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
AA BARRE — 120MG/5ML;12MG/5ML — N85861 001
APAP W/ CODEINE
AA BARRE — 120MG/5ML;12MG/5ML — N85861 001

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
AA KV PHARM — 300MG;30MG — N85288 001
AA — 300MG;60MG — N85365 001

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
KV PHARM — 325MG;15MG — N85364 001
325MG;45MG — N85363 001
@ — 300MG;30MG — N85288 001
@ — 300MG;60MG — N85365 001
@ — 325MG;15MG — N85364 001
@ — 325MG;45MG — N85363 001
AA MIKART — 650MG;30MG — N89231 001 MAR 03, 1986
\+ — 650MG;30MG — N89231 001 MAR 03, 1986
\+ ROXANE — 500MG;15MG — N89511 001 APR 25, 1989
\+ — 500MG;30MG — N89512 001 APR 25, 1989
\+ — 500MG;60MG — N89513 001 APR 25, 1989
@ — 500MG;15MG — N89511 001 APR 25, 1989
@ — 500MG;30MG — N89512 001 APR 25, 1989
@ — 500MG;60MG — N89513 001 APR 25, 1989
PHENAPHEN-650 W/ CODEINE
AA \+ ROBINS AH — 650MG;30MG — N85856 001
@ — 650MG;30MG — N85856 001

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
MIKART — 500MG/15ML;5MG/15ML — N89557 001 APR 29, 1992
— 500MG/15ML;7.5MG/15ML — N81051 001 AUG 28, 1992
\+ — 500MG/15ML;5MG/15ML — N89557 001 APR 29, 1992
\+ — 500MG/15ML;7.5MG/15ML — N81051 001 AUG 28, 1992

TABLET; ORAL
ANEXSIA
AA BOEHRINGER MANNHEIM — 500MG;5MG — N89160 001 APR 23, 1987

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >
> ADD >

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	ANEXSIA			
AA	KING PHARMS	500MG;5MG	N89160 001	APR 23, 1987
	ANEXSIA 7.5/650			
AA	BOEHRINGER MANNHEIM	650MG;7.5MG	N89725 001	SEP 30, 1987
AA	KING PHARMS	650MG;7.5MG	N89725 001	SEP 30, 1987
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	HALSEY	500MG;5MG	N89554 001	JUN 12, 1987
@		500MG;5MG	N89554 001	JUN 12, 1987
AA	KING PHARMS	500MG;5MG	N40084 002	JUN 01, 1995
AA		750MG;7.5MG	N40084 001	JUN 01, 1995
AA +	MIKART	650MG;10MG	N81223 001	MAY 29, 1992
AA	WATSON LABS	650MG;7.5MG	N40094 001	SEP 29, 1995
AA		650MG;10MG	N40094 002	SEP 29, 1995

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	ROXILOX			
AA	ROXANE	500MG;5MG	N40061 001	JUL 03, 1995

TABLET; ORAL

	OXYCET			
AA	HALSEY	325MG;5MG	N87463 001	DEC 07, 1983
AA	MALLINCKRODT	325MG;5MG	N87463 001	DEC 07, 1983

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DIAMOX			
+	STORZ OPHTHALM	500MG	N12945 001	
@		500MG	N12945 001	

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DIAMOX			
+	STORZ OPHTHALM	500MG	N12945 003	APR 25, 1995

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

	ACETAZOLAMIDE SODIUM			
AP	BEDFORD	EQ 500MG BASE/VIAL	N40089 001	FEB 28, 1995
AP	SANOFI WINTHROP	EQ 500MG BASE/VIAL	N40108 001	OCT 30, 1995
	DIAMOX			
AP +	STORZ OPHTHALM	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE			
AN	DUPONT MERCK	10%	N71364 001	MAY 01, 1989
AN		20%	N71365 001	MAY 01, 1989
AN	FAULDING	10%	N71364 001	MAY 01, 1989
AN		20%	N71365 001	MAY 01, 1989
AN	LUITPOLD	10%	N72489 001	JUL 28, 1995
AN		20%	N72547 001	JUL 28, 1995

ADENOSINE

INJECTABLE; INJECTION

	ADENOSCAN			
+	MEDCO RES	3MG/ML	N20059 001	MAY 18, 1995

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE
AN PACO — EQ 0.083% BASE — N73533 001 SEP 26, 1995

SYRUP; ORAL
ALBUTEROL SULFATE
AA BARRE — EQ 2MG BASE/5ML — N74454 001 SEP 25, 1995

ALENDRONATE SODIUM

TABLET; ORAL
FOSAMAX
MERCK — EQ 10MG BASE — N20560 001 SEP 29, 1995
\+ — EQ 40MG BASE — N20560 002 SEP 29, 1995

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM
AB CHELSEA LABS — 0.25MG — N74456 001 AUG 31, 1995
AB — 0.5MG — N74456 002 AUG 31, 1995
AB — 1MG — N74456 003 AUG 31, 1995

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT
UPJOHN — 0.01MG/VIAL — N20379 001 JUL 06, 1995
\+ — 0.02MG/VIAL — N20379 002 JUL 06, 1995

ALSEROXYLON

TABLET; ORAL
RAUWILOID
\+ 3M — 2MG — N08867 001

ALSEROXYLON

TABLET; ORAL
RAUWILOID
@ 3M — 2MG — N08867 001

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL
AA PHARM ASSOC — 50MG/5ML — N74509 001 JUL 17, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN
AP DUPONT MERCK — EQ 50MG BASE/ML — N63350 001 JUL 30, 1993
AP — EQ 250MG BASE/ML — N63350 002 JUL 30, 1993
AP + ELKINS SINN — EQ 50MG BASE/ML — N63274 001 MAY 18, 1992
AP + — EQ 250MG BASE/ML — N63275 001 MAY 18, 1992

AMIKACIN SULFATE
AP ELKINS SINN — EQ 50MG BASE/ML — N63274 001 MAY 18, 1992
AP — EQ 250MG BASE/ML — N63275 001 MAY 18, 1992
AP FAULDING — EQ 50MG BASE/ML — N63350 001 JUL 30, 1993
AP — EQ 250MG BASE/ML — N63350 002 JUL 30, 1993
AP SANOFI WINTHROP — EQ 250MG BASE/ML — N64098 001 JUN 26, 1995
AP — EQ 250MG BASE/ML — N64099 001 JUN 20, 1995

AMIKIN
AP APOTHECON — EQ 50MG BASE/ML — N62311 001
AP + — EQ 50MG BASE/ML — N62311 001
AP — EQ 250MG BASE/ML — N62311 002
AP + — EQ 250MG BASE/ML — N62311 002
@ — EQ 50MG BASE/ML — N62562 001 SEP 20, 1984
@ — EQ 250MG BASE/ML — N62562 002 SEP 20, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKIN

@ BRISTOL	EQ 50MG BASE/ML	N62562 001 SEP 20, 1984
@	EQ 250MG BASE/ML	N62562 002 SEP 20, 1984

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ APOTHECON	EQ 5MG BASE/ML	N50618 002 NOV 30, 1987
@	EQ 10MG BASE/ML	N50618 001 NOV 30, 1987
@ BRISTOL	EQ 5MG BASE/ML	N50618 002 NOV 30, 1987
@	EQ 10MG BASE/ML	N50618 001 NOV 30, 1987

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER	2.75%;10GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 002 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER	2.75%;15GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 003 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER	2.75%;20GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 004 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER	2.75%;25GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 005 OCT 23, 1995

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER	2.75%;5GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 001 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER	4.25%;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML	N20147 007 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER	4.25%;15GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML	N20147 008 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER	4.25%;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML	N20147 009 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER	4.25%;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML	N20147 010 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER	4.25%;5GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML	N20147 006 OCT 23, 1995

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER — 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML — N20177 001 — OCT 23, 1995

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER — 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML — N20173 001 — OCT 27, 1995 — >DLT>

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER — 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML — N20173 002 — OCT 27, 1995 — >DLT> >ADD>

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE
AP FUJISAWA — 25MG/ML — N87200 001
AP — 25MG/ML — N88407 001 — JAN 25, 1984
@ — 25MG/ML — N87200 001
@ — 25MG/ML — N88407 001 — JAN 25, 1984
AP KING PHARMS — 25MG/ML — N86606 001
@ — 25MG/ML — N86606 001

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
ABBOTT — 100MG/100ML — N88147 002 — MAY 03, 1983
200MG/100ML — N88147 003 — MAY 03, 1982
+ — 100MG/100ML — N88147 002 — MAY 03, 1983
+ — 200MG/100ML — N88147 003 — MAY 03, 1983

TABLET; ORAL
AMINOPHYLLINE
BD PHOENIX LABS NY — 100MG — N85409 001
BD — 200MG — N85410 001
@ — 100MG — N85409 001
@ — 200MG — N85410 001

AMINOSALICYLATE SODIUM

POWDER; ORAL
P.A.S. SODIUM
AA CENTURY PHARMS — 4GM/PACKET — N80947 001
@ — 4GM/PACKET — N80947 001
SODIUM AMINOSALICYLATE
AA HEXCEL — 100% — N80097 001
@ — 100% — N80097 001

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL
NEOPASALATE
+ WALLACE — 846MG;112MG — N80059 002
@ — 846MG;112MG — N80059 002

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
CORDARONE
+ WYETH AYERST — 50MG/ML — N20377 001 — AUG 03, 1995

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL
AB ROXANE — 150MG — N86090 001
@ — 150MG — N86090 001

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
LOTREL
CIBA GEIGY — EQ 2.5MG BASE;10MG — N20364 002 — MAR 03, 1995
EQ 5MG BASE;10MG — N20364 003 — MAR 03, 1995
+ — EQ 5MG BASE;20MG — N20364 004 — MAR 03, 1995

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	CONSOLIDATED PHARM	250MG	N62058 001	
AB		500MG	N62058 002	
	COMOX			
AB	COPANOS	250MG	N62058 001	
AB		500MG	N62058 002	
	POLYMOX			
AB	APOTHECON	250MG	N63099 001	MAR 20, 1992
AB		500MG	N63099 002	MAR 20, 1992
	TRIMOX			
AB	APOTHECON	250MG	N63099 001	MAR 20, 1992
AB		500MG	N63099 002	MAR 20, 1992

POWDER FOR RECONSTITUTION; ORAL

	AMOXICILLIN			
AB	CONSOLIDATED PHARM	125MG/5ML	N62059 001	
AB		250MG/5ML	N62059 002	
	AMOXICILLIN TRIHYDRATE			
AB	COPANOS	125MG/5ML	N62059 001	
AB		250MG/5ML	N62059 002	

AMPHOTERICIN B

INJECTABLE; INJECTION

> ADD >	ABELCET			
> ADD >	+ LIPOSOME	5MG/ML	N50724 001	
> ADD >			NOV 20, 1995	
	AMPHOTERICIN B			
AP	GENSIA	50MG/VIAL	N64062 001	MAR 31, 1995

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	AMPICILLIN SODIUM			
AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001	
AP		EQ 125MG BASE/VIAL	N62860 001	FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	AMPICILLIN SODIUM			
AP	APOTHECON	EQ 250MG BASE/VIAL	N62860 002	FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003	
AP		EQ 500MG BASE/VIAL	N62860 003	FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004	
AP		EQ 1GM BASE/VIAL	N62738 001	FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005	
AP		EQ 2GM BASE/VIAL	N62738 002	FEB 19, 1987
AP		EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988
AP	+	EQ 10GM BASE/VIAL	N61395 006	
	@ CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	N61936 005	
	@	EQ 250MG BASE/VIAL	N61936 001	
	@	EQ 500MG BASE/VIAL	N61936 002	
	@	EQ 1GM BASE/VIAL	N61936 003	
	@	EQ 2GM BASE/VIAL	N61936 004	
	@ COPANOS	EQ 125MG BASE/VIAL	N61936 005	
	@	EQ 250MG BASE/VIAL	N61936 001	
	@	EQ 500MG BASE/VIAL	N61936 002	
	@	EQ 1GM BASE/VIAL	N61936 003	
	@	EQ 2GM BASE/VIAL	N61936 004	
	PRINCIPEN			
AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001	
AP		EQ 125MG BASE/VIAL	N62860 001	FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002	
AP		EQ 250MG BASE/VIAL	N62860 002	FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003	
AP		EQ 500MG BASE/VIAL	N62860 003	FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004	
AP		EQ 1GM BASE/VIAL	N62738 001	FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005	
AP		EQ 2GM BASE/VIAL	N62738 002	FEB 19, 1987

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	PRINCIPEN			
AP	APOTHECON	EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988
AP +		EQ 10GM BASE/VIAL	N61395 006	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	AMPICILLIN TRIHYDRATE			
AB	BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995
AB		EQ 500MG BASE	N64082 002	AUG 29, 1995
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	
AB	COPANOS	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	

POWDER FOR RECONSTITUTION; ORAL

	AMPICILLIN TRIHYDRATE			
AB	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
AB	COPANOS	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
	POLYCILLIN			
AB +	BRISTOL	EQ 125MG BASE/5ML	N50308 001	
AB +		EQ 250MG BASE/5ML	N50308 002	
+		EQ 500MG BASE/5ML	N50308 003	
@		EQ 125MG BASE/5ML	N50308 001	
@		EQ 250MG BASE/5ML	N50308 002	
@		EQ 500MG BASE/5ML	N50308 003	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	VASOCON-A			
+	CIBA VISION	0.5%;0.05%	N18746 001	APR 30, 1990

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE			
AB	WATSON LABS	325MG;50MG;40MG;30MG	N74359 001	AUG 31, 1995
	FIORINAL W/CODEINE NO 3			
AB +	SANDOZ	325MG;50MG;40MG;30MG	N19429 003	OCT 26, 1990

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL AND ASPIRIN			
AB	STEVENS J	325MG;400MG	N81145 001	JAN 31, 1995

ATENOLOL

TABLET; ORAL

	ATENOLOL			
AB	COPLEY PHARM	50MG	N74120 001	FEB 24, 1995
AB		100MG	N74120 002	FEB 24, 1995
AB	LEMMON	50MG	N74056 001	JAN 18, 1995
AB		100MG	N74056 002	JAN 18, 1995
AB	MARTEC	50MG	N74127 001	FEB 21, 1995
AB		100MG	N74127 002	FEB 21, 1995

ATOVAQUONE

SUSPENSION; ORAL

	MEPRON			
+	GLAXO WELLCOME	750MG/5ML	N20500 001	FEB 08, 1995

ATROPINE

INJECTABLE; INJECTION

	ATROPEN			
AP +	SURVIVAL TECH	EQ 2MG SULFATE/0.7ML	N17106 001	

ATROPINE

INJECTABLE; INJECTION

		ATROPEN		
	+	SURVIVAL TECH	EQ 2MG SULFATE/0.7ML	N17106 001
		ATROPINE		
AP		KALI DUPHAR	EQ 2MG SULFATE/0.7ML	N71295 001 JAN 30, 1987
	@	SOLVAY	EQ 2MG SULFATE/0.7ML	N71295 001 JAN 30, 1987

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

> DLT >		DI-ATRO		
> DLT >	AA	MD PHARM	0.025MG;2.5MG	N85266 001
> ADD >	@		0.025MG;2.5MG	N85266 001

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

		AZATHIOPRINE SODIUM		
AP		BEDFORD	EQ 100MG BASE/VIAL	N74419 001 MAR 31, 1995
		IMURAN		
AP	+	GLAXO WELLCOME	EQ 100MG BASE/VIAL	N17391 001

AZELAIC ACID

CREAM; TOPICAL

		AZELEX		
	+	ALLERGAN	20%	N20428 001 SEP 13, 1995

AZITHROMYCIN DIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

		ZITHROMAX		
	+	PFIZER	EQ 100MG BASE/5ML	N50710 001 OCT 19, 1995
	+		EQ 200MG BASE/5ML	N50710 002 OCT 19, 1995

BACITRACIN

INJECTABLE; INJECTION

		BACITRACIN		
AP	+	PFIZER	50,000 UNITS/VIAL	N60282 001
	@		50,000 UNITS/VIAL	N60282 001
AP		UPJOHN	50,000 UNITS/VIAL	N60733 002
	+		50,000 UNITS/VIAL	N60733 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		CORTISPORIN		
AT	+	GLAXO WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50416 002
		NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE		
AT		BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64068 001 OCT 30, 1995

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC		
AT		BAUSCH AND LOMB	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64064 001 OCT 30, 1995

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		BACITRACIN ZINC AND POLYMYXIN B SULFATE		
AT		ADV REMEDIES	500 UNITS/GM; 10,000 UNITS/GM	N64028 001 JAN 30, 1995
AT		BAUSCH AND LOMB	500 UNITS/GM; 10,000 UNITS/GM	N64046 001 JAN 26, 1995
		POLYSPORIN		
AT	+	GLAXO WELLCOME	500 UNITS/GM; 10,000 UNITS/GM	N61229 001

BENDROFLUMETHIAZIDE

TABLET; ORAL			
NATURETIN-10			
+ APOTHECON	10MG	N12164 003	
+ SQUIBB	10MG	N12164 003	
NATURETIN-2.5			
@ APOTHECON	2.5MG	N12164 001	
@ SQUIBB	2.5MG	N12164 001	
NATURETIN-5			
APOTHECON	5MG	N12164 002	
SQUIBB	5MG	N12164 002	

BENTONITE; SULFUR

POWDER; TOPICAL		
BENSULFOID		
@ POYTHRESS	66.64%;33.32%	N02918 001

BETAMETHASONE BENZOATE

GEL; TOPICAL		
UTICORT		
+ PARKE DAVIS	0.025%	N17244 001
@	0.025%	N17244 001
LOTION; TOPICAL		
UTICORT		
+ PARKE DAVIS	0.025%	N17528 001
@	0.025%	N17528 001

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL			
BETAMETHASONE DIPROPIONATE			
AB NMC	**EQ 0.05% BASE**	**N74304 001** AUG 31, 1995	
DIPROLENE			
AB + SCHERING	**EQ 0.05% BASE**	**N18741 001** JUL 27, 1983	

BICALUTAMIDE

TABLET; ORAL		
CASODEX		
+ ZENECA	50MG	N20498 001 OCT 04, 1995

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION			
BRETYLOL			
AP DUPONT MERCK	**50MG/ML**	**N17954 001**	
AP FAULDING	50MG/ML	N17954 001	

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL			
DIMETANE-DC			
AA ROBINS AH	**2MG/5ML;10MG/5ML; 12.5MG/5ML**	**N11694 006** MAR 29, 1984	
AA +	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006 MAR 29, 1984	

BUMETANIDE

INJECTABLE; INJECTION			
BUMETANIDE			
AP BEDFORD	**0.25MG/ML**	**N74441 001** JAN 27, 1995	
TABLET; ORAL			
BUMETANIDE			
AB ZENITH LABS	**0.5MG**	**N74225 001** APR 24, 1995	
AB	**1MG**	**N74225 002** APR 24, 1995	
AB	**2MG**	**N74225 003** APR 24, 1995	
BUMEX			
AB ROCHE	**0.5MG**	**N18225 002** FEB 28, 1983	
AB	**1MG**	**N18225 001** FEB 28, 1983	

BUMETANIDE

TABLET; ORAL
BUMEX
AB + ROCHE 2MG N18225 003
JUN 14, 1985

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
MARCAINE HCL
AP + SANOFI WINTHROP 0.25% N16964 001
AP + 0.5% N16964 006
AP + STERLING WINTHROP 0.25% N16964 001
AP + 0.5% N16964 006
> DLT > AP + 0.75% N16964 009
MARCAINE HCL PRESERVATIVE FREE
> ADD > AP + SANOFI WINTHROP 0.25% N16964 012
AP + 0.5% N16964 005
> ADD > AP + 0.75% N16964 009

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
MARCAINE HCL W/ EPINEPHRINE
AP + SANOFI WINTHROP 0.25%;0.0091MG/ML N16964 004
AP + 0.5%;0.0091MG/ML N16964 008
AP + STERLING WINTHROP 0.25%;0.0091MG/ML N16964 004
AP + 0.5%;0.0091MG/ML N16964 008
> DLT > AP + 0.75%;0.0091MG/ML N16964 010
> ADD > MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE
> ADD > AP + SANOFI WINTHROP 0.25%;0.0091MG/ML N16964 013
> ADD > AP + 0.5%;0.0091MG/ML N16964 007
> ADD > AP + 0.75%;0.0091MG/ML N16964 010

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
STADOL
> DLT > + APOTHECON 1MG/ML N17857 001 > ADD >
> DLT > + 2MG/ML N17857 002 > ADD >
> ADD > + 2MG/ML N17857 004 > ADD >
> ADD > > ADD >
> ADD > STADOL PRESERVATIVE FREE
> ADD > + APOTHECON 1MG/ML N17857 001 > ADD >
> ADD > + 2MG/ML N17857 002 > ADD >

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL
CAFERGOT
AA + SANDOZ 100MG;1MG N06620 001
@ 100MG;1MG N06620 001
ERCATAB
AA GENEVA PHARMS 100MG;1MG N84294 001
AA + 100MG;1MG N84294 001

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCITONIN-SALMON
AP ASTRA 200 IU/ML N73690 001
APR 14, 1995

SPRAY, METERED; NASAL
MIACALCIN
+ SANDOZ 200 IU/INH N20313 002
AUG 17, 1995

CAPTOPRIL

TABLET; ORAL
CAPOTEN
AB BRISTOL MYERS SQUIBB 12.5MG N18343 005
JAN 17, 1985
AB 25MG N18343 002
AB 50MG N18343 001
AB + 100MG N18343 003
CAPTOPRIL
AB APOTHECON 12.5MG N74472 001
MAR 31, 1995
AB 25MG N74472 002
MAR 31, 1995
AB 50MG N74472 003
MAR 31, 1995
AB 100MG N74472 004
MAR 31, 1995
AB GENEVA PHARMS 12.5MG N74363 001
NOV 09, 1995
AB 25MG N74363 002
NOV 09, 1995
AB 50MG N74363 003
NOV 09, 1995

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

> ADD >	AB	GENEVA PHARMS	100MG	N74363 004 NOV 09, 1995
> ADD				

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPOZIDE 25/25

	SQUIBB	25MG;25MG	N18709 002 OCT 12, 1984
+		25MG;25MG	N18709 002 OCT 12, 1984

CAPOZIDE 50/15

	SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984
+		50MG;15MG	N18709 004 OCT 12, 1984

CAPOZIDE 50/25

+	SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984
		50MG;25MG	N18709 003 OCT 12, 1984

CARBACHOL

SOLUTION; INTRAOCULAR
CARBASTAT

AT		CIBA	0.01%	N73677 001 APR 28, 1995

MIOSTAT

AT	+	ALCON	0.01%	N16968 001

CARBAMAZEPINE

TABLET; ORAL
TEGRETOL

> DLT >	AB	+	BASEL PHARMS	200MG	N16608 001
> ADD >	AB	+	CIBA GEIGY	200MG	N16608 001

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

AB		GENEVA PHARMS	10MG;100MG	N73586 001 JUN 29, 1995
AB			25MG;100MG	N73587 001 JUN 29, 1995
AB			25MG;250MG	N73620 001 JUN 29, 1995

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUPRESS

+	OTSUKA	1%	N19972 001 MAY 23, 1990

OPTIPRESS

+	OTSUKA	1%	N19972 001 MAY 23, 1990

CARVEDILOL

TABLET; ORAL
COREG

	SMITHKLINE BEECHAM	6.25MG	N20297 003 SEP 14, 1995
		12.5MG	N20297 002 SEP 14, 1995
+		25MG	N20297 001 SEP 14, 1995

CEFACLOR

CAPSULE; ORAL
CECLOR

AB	+	LILLY	EQ 250MG BASE	N50521 001
AB			EQ 250MG BASE	N62205 001
AB	+		EQ 500MG BASE	N50521 002
AB			EQ 500MG BASE	N62205 002

CEFACLOR

AB		LEDERLE	EQ 250MG BASE	N64107 001 APR 27, 1995
AB			EQ 500MG BASE	N64107 002 APR 27, 1995

CEFACLOR

CAPSULE; ORAL

		CEFACLOR		
AB		ZENITH LABS	EQ 250MG BASE	N64061 001 APR 27, 1995
AB			EQ 500MG BASE	N64061 002 APR 27, 1995

POWDER FOR RECONSTITUTION; ORAL

		CECLOR		
AB	+	LILLY	EQ 125MG BASE/5ML	N50522 001
AB			EQ 125MG BASE/5ML	N62206 001
AB	+		EQ 187MG BASE/5ML	N62206 003 APR 20, 1988
AB	+		EQ 250MG BASE/5ML	N50522 002
AB			EQ 250MG BASE/5ML	N62206 002
AB	+		EQ 375MG BASE/5ML	N62206 004 APR 20, 1988
		CEFACLOR		
AB		LEDERLE	EQ 125MG BASE/5ML	N64114 001 APR 28, 1995
AB			EQ 187MG BASE/5ML	N64115 001 APR 28, 1995
AB			EQ 250MG BASE/5ML	N64116 001 APR 28, 1995
AB			EQ 375MG BASE/5ML	N64110 001 APR 28, 1995
AB		ZENITH LABS	EQ 125MG BASE/5ML	N64087 001 APR 28, 1995
AB			EQ 187MG BASE/5ML	N64086 001 APR 28, 1995
AB			EQ 250MG BASE/5ML	N64085 001 APR 28, 1995
AB			EQ 375MG BASE/5ML	N64070 001 APR 28, 1995

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

		MANDOL		
	+	LILLY	EQ 500MG BASE/VIAL	N50504 001
	@		EQ 500MG BASE/VIAL	N50504 001

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

		CEFAZOLIN SODIUM		
AP		APOTHECON	EQ 500MG BASE/VIAL	N62831 001 DEC 09, 1988
AP			EQ 1GM BASE/VIAL	N62831 002 DEC 09, 1988
AP			EQ 10GM BASE/VIAL	N62831 003 SEP 25, 1992
AP		ELKINS SINN	EQ 250MG BASE/VIAL	N62807 001 JAN 12, 1988
AP			EQ 500MG BASE/VIAL	N62807 002 JAN 12, 1988
AP			EQ 1GM BASE/VIAL	N62807 003 JAN 12, 1988
AP			EQ 5GM BASE/VIAL	N62807 004 JAN 12, 1988
AP			EQ 10GM BASE/VIAL	N62807 005 JAN 12, 1988
AP			EQ 20GM BASE/VIAL	N62807 006 JAN 12, 1988
	@		EQ 250MG BASE/VIAL	N62807 001 JAN 12, 1988
	@		EQ 500MG BASE/VIAL	N62807 002 JAN 12, 1988
	@		EQ 1GM BASE/VIAL	N62807 003 JAN 12, 1988
	@		EQ 5GM BASE/VIAL	N62807 004 JAN 12, 1988
	@		EQ 10GM BASE/VIAL	N62807 005 JAN 12, 1988
	@		EQ 20GM BASE/VIAL	N62807 006 JAN 12, 1988
		ZOLICEF		
AP		APOTHECON	EQ 500MG BASE/VIAL	N62831 001 DEC 09, 1988
AP			EQ 1GM BASE/VIAL	N62831 002 DEC 09, 1988
AP			EQ 10GM BASE/VIAL	N62831 003 SEP 25, 1992

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

		CEFOBID		
		PFIZER	EQ 1GM BASE/VIAL	N63333 001 MAR 31, 1995

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

	CEFOBID						
	PFIZER	EQ 2GM BASE/VIAL	N63333 002 MAR 31, 1995	> ADD > > ADD > > ADD > > ADD >			

CEFORANIDE

INJECTABLE; INJECTION

	PRECEF						
	APOTHECON	500MG/VIAL	N62579 001 NOV 26, 1984				
		1GM/VIAL	N62579 002 NOV 26, 1984				
		2GM/VIAL	N62579 003 NOV 26, 1984				
		10GM/VIAL	N62579 004 NOV 26, 1984				
		20GM/VIAL	N62579 005 NOV 26, 1984				
	BRISTOL	500MG/VIAL	N62579 001 NOV 26, 1984				
		1GM/VIAL	N62579 002 NOV 26, 1984				
		2GM/VIAL	N62579 003 NOV 26, 1984				
		10GM/VIAL	N62579 004 NOV 26, 1984				
		20GM/VIAL	N62579 005 NOV 26, 1984				

CEFOXITIN SODIUM

INJECTABLE; INJECTION

	MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
+	MERCK SHARP DOHME	EQ 20MG BASE/ML	N50581 002 SEP 20, 1984				
+		EQ 40MG BASE/ML	N50581 001 SEP 20, 1984				
@		EQ 20MG BASE/ML	N50581 002 SEP 20, 1984				
@		EQ 40MG BASE/ML	N50581 001 SEP 20, 1984				

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	PENTACEF						
AP	SMITHKLINE BEECHAM	**1GM/VIAL**	**N63322 001** NOV 07, 1995				
AP		**2GM/VIAL**	**N63322 002** NOV 07, 1995				

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

	ROCEPHIN						
AP	+ ROCHE	**EQ 250MG BASE/VIAL**	**N50585 001** DEC 21, 1984				
AP	+	**EQ 500MG BASE/VIAL**	**N50585 002** DEC 21, 1984				
AP	+	**EQ 1GM BASE/VIAL**	**N50585 003** DEC 21, 1984				
	+	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984				
	+	EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984				
	+	EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984				

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	KEFUROX						
AP	+ LILLY	**EQ 7.5GM BASE/VIAL**	**N62591 003** DEC 17, 1987				
AP		**EQ 7.5GM BASE/VIAL**	**N62591 003** DEC 17, 1987				
	ZINACEF						
AP	GLAXO	**EQ 7.5GM BASE/VIAL**	**N50558 004** OCT 23, 1986				
AP	+ GLAXO WELLCOME	**EQ 7.5GM BASE/VIAL**	**N50558 004** OCT 23, 1986				

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

	CEPHALEXIN						
AB	APOTHECON	**EQ 125MG BASE/5ML**	**N62986 001** APR 18, 1991				

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

	CEPHALEXIN			
AB	APOTHECON	**EQ 250MG BASE/5ML**	**N62987 001**	JUL 25, 1989
AB	SQUIBB MARK	**EQ 125MG BASE/5ML**	**N62986 001**	APR 18, 1991
AB		**EQ 250MG BASE/5ML**	**N62987 001**	JUL 25, 1989

CEPHRADINE

CAPSULE; ORAL

	VELOSEF			
AB	+ APOTHECON	**250MG**	**N61764 001**	
AB	+	**500MG**	**N61764 002**	
AB	+ ERSANA	**250MG**	**N61764 001**	
AB	+	**500MG**	**N61764 002**	

INJECTABLE; INJECTION

VELOSEF			
+ APOTHECON	250MG/VIAL	N61976 001	
+	500MG/VIAL	N61976 002	
+	1GM/VIAL	N61976 004	
+	2GM/VIAL	N61976 003	
+	4GM/VIAL	N61976 005	
+ SQUIBB	250MG/VIAL	N61976 001	
+	500MG/VIAL	N61976 002	
+	1GM/VIAL	N61976 004	
+	2GM/VIAL	N61976 003	
+	4GM/VIAL	N61976 005	

POWDER FOR RECONSTITUTION; ORAL

VELOSEF '125'			
AB + APOTHECON	**125MG/5ML**	**N61763 001**	
AB + ERSANA	**125MG/5ML**	**N61763 001**	
VELOSEF '250'			
AB + APOTHECON	**250MG/5ML**	**N61763 002**	
AB + ERSANA	**250MG/5ML**	**N61763 002**	

CHLORAMPHENICOL

CAPSULE; ORAL

	MYCHEL			
AB	ARMENPHARM	**250MG**	**N60851 001**	
AB	RACHELLE	**250MG**	**N60851 001**	

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC

	OPTOMYCIN			
AT	OPTOPICS	**0.5%**	**N62171 001**	MAR 31, 1982
@		0.5%	N62171 001	MAR 31, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

	CHLORAMPHENICOL			
AP	ELKINS SINN	**EQ 1GM BASE/VIAL**	**N62406 001**	NOV 09, 1982
@		EQ 1GM BASE/VIAL	N62406 001	NOV 09, 1982

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 10-4			
ROCHE	10MG;0.4MG	N14740 006	
@	10MG;0.4MG	N14740 006	
MENRIUM 5-2			
ROCHE	5MG;0.2MG	N14740 002	
@	5MG;0.2MG	N14740 002	
MENRIUM 5-4			
+ ROCHE	5MG;0.4MG	N14740 004	
@	5MG;0.4MG	N14740 004	

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

	CHLORPHENIRAMINE MALEATE			
AP	STERIS	**10MG/ML**	**N83593 001**	
		100MG/ML	**N86095 001**	
@		10MG/ML	N83593 001	
@		100MG/ML	N86095 001	

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CHLORPROMAZINE HCL			
AP	STERIS	**25MG/ML**	**N85591 001**	

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL
@ STERIS 25MG/ML N85591 001

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE
AB LEMMON 100MG N88768 001 OCT 11, 1984
@ 100MG N88768 001 OCT 11, 1984

GLUCAMIDE
AB LEMMON 250MG N88641 001 OCT 11, 1984
@ 250MG N88641 001 OCT 11, 1984

CHLORPROTHIXENE

> DLT > CONCENTRATE; ORAL
> DLT > TARACTAN
> DLT > ROCHE 100MG/5ML N16149 002
> ADD > @ 100MG/5ML N16149 002

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE
AB MUTUAL PHARM 25MG N89738 001 SEP 19, 1988
AB 50MG N89739 001 SEP 19, 1988
@ 25MG N89738 001 SEP 19, 1988
@ 50MG N89739 001 SEP 19, 1988

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE
AA AMIDE PHARM 500MG N40113 001 SEP 29, 1995

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL
CHOLYBAR
+ PARKE DAVIS EQ 4GM RESIN/BAR N71621 001 MAY 26, 1988
EQ 4GM RESIN/BAR N71739 001 MAY 26, 1988
@ EQ 4GM RESIN/BAR N71621 001 MAY 26, 1988
@ EQ 4GM RESIN/BAR N71739 001 MAY 26, 1988

TABLET; ORAL
QUESTRAN
+ BRISTOL MYERS SQUIBB EQ 1GM RESIN N73403 001 APR 28, 1994
@ EQ 1GM RESIN N73403 001 APR 28, 1994

CIMETIDINE

TABLET; ORAL
CIMETIDINE
AB BAKER NORTON 200MG N74424 001 JUL 28, 1995
AB 300MG N74424 002 JUL 28, 1995
AB 400MG N74424 003 JUL 28, 1995
AB 800MG N74424 004 JUL 28, 1995
AB GENEVA PHARMS 200MG N74100 001 JAN 31, 1995
AB 300MG N74100 002 JAN 31, 1995
AB 400MG N74100 003 JAN 31, 1995
AB 800MG N74100 004 JAN 31, 1995
AB LEK LJUBLJANA 200MG N74250 001 JUN 29, 1995
AB 300MG N74250 002 JUN 29, 1995
AB 400MG N74250 003 JUN 29, 1995
AB 800MG N74250 004 JUN 29, 1995

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	LEMMON	200MG	N74365 001 FEB 28, 1995		
AB		300MG	N74365 002 FEB 28, 1995	> ADD >	
AB		400MG	N74365 003 FEB 28, 1995	> ADD >	
AB		800MG	N74365 004 FEB 28, 1995		
AB	MOVA	300MG	N74340 001 JUN 23, 1995		
AB		400MG	N74340 002 JUN 23, 1995		
AB		800MG	N74339 001 JUN 23, 1995		
AB	ZENITH LABS	200MG	N74401 001 MAY 30, 1995		
AB		300MG	N74401 002 MAY 30, 1995		
AB		400MG	N74401 003 MAY 30, 1995		
AB		800MG	N74402 001 MAY 30, 1995		

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	ABBOTT	EQ 300MG BASE/2ML	N74344 001 JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74345 001 JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74422 001 JAN 31, 1995

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL
PROPULSID

+	JANSSEN	EQ 1MG BASE/ML	N20398 001 SEP 15, 1995

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLEOCIN

	UPJOHN	EQ 1% BASE	N50537 002 FEB 22, 1994

CLINDAMYCIN PHOSPHATE

AT	CLAY PARK	EQ 1% BASE	N64050 001 NOV 30, 1995	> ADD >	

SWAB; TOPICAL
CLEOCIN

UPJOHN	EQ 1% BASE	N50537 002 FEB 22, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL
TEMOVATE E

BX	+ GLAXO WELLCOME	0.05%	N20340 001 JUN 17, 1994

TEMOVATE EMOLLIENT

BX	+ GLAXO	0.05%	N20340 001 JUN 17, 1994

OINTMENT; TOPICAL
EMBELINE

AB	DPT	0.05%	N74221 001 MAR 31, 1995

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE

AB	GENEVA PHARMS	500MG	N72191 001 MAY 02, 1988
	@	500MG	N72191 001 MAY 02, 1988

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL

BASEL PHARMS	50MG	N19906 002 DEC 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL
\+ BASEL PHARMS 75MG N19906 003 DEC 29, 1989
\+ 50MG N19906 002 DEC 29, 1989
75MG N19906 003 DEC 29, 1989

CLOTRIMAZOLE

SOLUTION; TOPICAL
CLOTRIMAZOLE
AT LEMMON 1% N73306 001 FEB 28, 1995

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXACILLIN SODIUM
AB + APOTHECON EQ 250MG BASE N61452 001
AB + EQ 500MG BASE N61452 002
TEGOPEN
AB + APOTHECON EQ 250MG BASE N61452 001
AB + EQ 500MG BASE N61452 002

POWDER FOR RECONSTITUTION; ORAL
TEGOPEN
@ APOTHECON EQ 125MG BASE/5ML N50192 001
AA BRISTOL EQ 125MG BASE/5ML N50192 001

CLOZAPINE

TABLET; ORAL
CLOZARIL
SANDOZ 25MG N19758 001 SEP 26, 1989
\+ 100MG N19758 002 SEP 26, 1989
\+ 25MG N19758 001 SEP 26, 1989
100MG N19758 002 SEP 26, 1989

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL
COLESTID
UPJOHN 5GM/SCOOPFUL N17563 003 SEP 22, 1995
\+ 5GM/PACKET N17563 004 SEP 22, 1995

COLISTIN SULFATE

SUSPENSION; ORAL
COLY-MYCIN S
PARKE DAVIS EQ 25MG BASE/5ML N50355 001
@ EQ 25MG BASE/5ML N50355 001

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH
AP PARKE DAVIS 40 UNITS/VIAL N08317 004
@ 40 UNITS/VIAL N08317 004

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC
CROLOM
AT BAUSCH AND LOMB 4% N74443 001 JAN 30, 1995

OPTICROM
AT + FISONS 4% N18155 001 OCT 03, 1984

CUPRIC SULFATE

INJECTABLE; INJECTION
CUPRIC SULFATE
\+ FUJISAWA EQ 0.4MG COPPER/ML N19350 001 MAY 05, 1987
@ EQ 0.4MG COPPER/ML N19350 001 MAY 05, 1987

CYANOCOBALAMIN

INJECTABLE; INJECTION

		CYANOCOBALAMIN		
AP		**AKORN**	**1MG/ML**	**N87969 001**
				NOV 10, 1983
	@		1MG/ML	N87969 001
				NOV 10, 1983
	@	WARNER CHILCOTT	1MG/ML	N07085 002
		RUBRAMIN PC		
AP	+	**SQUIBB**	**0.1MG/ML**	**N06799 002**
	@		0.1MG/ML	N06799 002
		SYTOBEX		
AP		**PARKE DAVIS**	**1MG/ML**	**N07085 002**

CYCLACILLIN

TABLET; ORAL

			CYCLACILLIN		
> DLT >	**AB**		**BIOCRAFT**	**250MG**	**N62895 001**
> DLT >					**AUG 04, 1988**
> DLT >	**AB**			**500MG**	**N62895 002**
> DLT >					**AUG 04, 1988**
> ADD >		+		250MG	N62895 001
> ADD >					AUG 04, 1988
> ADD >		+		500MG	N62895 002
> ADD >					AUG 04, 1988
> DLT >			**CYCLAPEN-W**		
> DLT >	**AB**	+	**WYETH AYERST**	**250MG**	**N50509 001**
> DLT >	**AB**	+		**500MG**	**N50509 002**
> ADD >		@		250MG	N50509 001
> ADD >		@		500MG	N50509 002

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

	CYCLOBENZAPRINE HCL		
AB	**BARR**	**10MG**	**N73541 001**
			MAY 23, 1995
AB	SIDMAK LABS NJ	**10MG**	**N74421 001**
			SEP 29, 1995

CYCLOSPORINE

CAPSULE; ORAL

		NEORAL		
BP		SANDOZ	25MG	N50715 001
				JUL 14, 1995
BP			50MG	N50715 003
				JUL 14, 1995
BP	+		100MG	N50715 002
				JUL 14, 1995
			25MG	N50715 001
				JUL 14, 1995
			50MG	N50715 003
				JUL 14, 1995
	+		100MG	N50715 002
				JUL 14, 1995
		SANDIMMUNE		
BP		SANDOZ	25MG	N50625 001
				MAR 02, 1990
BP			50MG	N50625 003
				NOV 23, 1992
BP	+		100MG	N50625 002
				MAR 02, 1990
			25MG	N50625 001
				MAR 02, 1990
			50MG	N50625 003
				NOV 23, 1992
	+		100MG	N50625 002
				MAR 02, 1990

SOLUTION; ORAL

		NEORAL		
BP	+	SANDOZ	100MG/ML	N50716 001
				JUL 14, 1995
	+		100MG/ML	N50716 001
				JUL 14, 1995
		SANDIMMUNE		
BP	+	SANDOZ	100MG/ML	N50574 001
				NOV 14, 1983
	+		100MG/ML	N50574 001
				NOV 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

	CYPROHEPTADINE HCL		
AA	**ASCOT**	**4MG**	**N87685 001**
			OCT 25, 1982

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL

	@	ASCOT	4MG	N87685 001 OCT 25, 1982

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL

AP		CETUS BEN VENUE	EQ 20MG BASE/VIAL	N64103 001 FEB 03, 1995

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DDAVP

	+	RHONE POULENC	0.015MG/ML	N18938 002 APR 25, 1995

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE

	+	RHONE POULENC RORER	0.15MG/INH	N20355 001 MAR 07, 1994

STIMATE

	+	RHONE POULENC RORER	0.15MG/INH	N20355 001 MAR 07, 1994

TABLET; ORAL
DDAVP

		RHONE POULENC RORER	0.1MG	N19955 001 SEP 06, 1995
	+		0.2MG	N19955 002 SEP 06, 1995

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGEN

AB	+	ORGANON	0.15MG;0.03MG	N20071 001 DEC 10, 1992
	@		0.15MG;0.03MG	N20071 001 DEC 10, 1992

ORTHO-CEPT

AB		JOHNSON RW	0.15MG;0.03MG	N20301 001 DEC 14, 1992

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
ORTHO-CEPT

		JOHNSON RW	0.15MG;0.03MG	N20301 001 DEC 14, 1992

DEXAMETHASONE

AEROSOL; TOPICAL
DECASPRAY

	+	MERCK SHARP DOHME	0.4%	N12731 002
	+		0.04%	N12731 002

TABLET; ORAL
HEXADROL

BP		ORGANON	0.5MG	N12675 004
BP			0.75MG	N12675 007
BP			1.5MG	N12675 009
	@		0.5MG	N12675 004
	@		0.75MG	N12675 007
	@		1.5MG	N12675 009

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
DEXASPORIN

AT		BAUSCH AND LOMB	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N64135 001 SEP 13, 1995

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE

AP		FUJISAWA	EQ 4MG PHOSPHATE/ML	N88448 001 JAN 25, 1984
	@		EQ 4MG PHOSPHATE/ML	N88448 001 JAN 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

AP		AKORN	EQ 4MG PHOSPHATE/ML	N84493 001
	@		EQ 4MG PHOSPHATE/ML	N84493 001

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

AT	BAUSCH AND LOMB	**EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML**	**N64055 001** OCT 30, 1995	

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
ZINECARD

+	PHARMACIA	EQ 250MG BASE/VIAL	N20212 001 MAY 26, 1995	
+		EQ 500MG BASE/VIAL	N20212 002 MAY 26, 1995	

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 2.5% IN PLASTIC CONTAINER

	MCGAW	2.5GM/100ML	N19626 001 FEB 02, 1988	
@		2.5GM/100ML	N19626 001 FEB 02, 1988	

DEXTROSE 5% IN PLASTIC CONTAINER

AP	DHL	**5GM/100ML**	**N19971 001** SEP 28, 1995	

DEXTROSE 7.7% IN PLASTIC CONTAINER

	MCGAW	7.7GM/100ML	N19626 003 FEB 02, 1988	
@		7.7GM/100ML	N19626 003 FEB 02, 1988	

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

AP	FUJISAWA	**5MG/ML**	**N70662 001** JUN 25, 1986	
@		5MG/ML	N70662 001 JUN 25, 1986	

> ADD >
> ADD >

DICLOFENAC POTASSIUM

TABLET; ORAL
CATAFLAM

	GEIGY	25MG	**N20142 001** NOV 24, 1993	
@		25MG	N20142 001 NOV 24, 1993	

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

AB	GENEVA PHARMS	**25MG**	**N74376 001** SEP 28, 1995	
AB		**50MG**	**N74376 002** SEP 28, 1995	
AB		**75MG**	**N74394 001** NOV 30, 1995	
AB	ROXANE	**25MG**	**N74391 001** JUN 29, 1995	
AB		**50MG**	**N74391 002** JUN 29, 1995	
AB		**75MG**	**N74391 003** JUN 29, 1995	

VOLTAREN

AB	+ GEIGY	**25MG**	**N19201 001** JUL 28, 1988	
AB	+	**50MG**	**N19201 002** JUL 28, 1988	
AB	+	**75MG**	**N19201 003** JUL 28, 1988	

DICLOXACILLIN SODIUM

CAPSULE; ORAL
DICLOXACILLIN SODIUM

AB	APOTHECON	**EQ 250MG BASE**	**N61454 001**
AB		**EQ 500MG BASE**	**N61454 003**
		EQ 125MG BASE	N61454 002

DYNAPEN

AB	APOTHECON	**EQ 250MG BASE**	**N61454 001**
AB		**EQ 500MG BASE**	**N61454 003**
		EQ 125MG BASE	N61454 002

POWDER FOR RECONSTITUTION; ORAL
DICLOXACILLIN SODIUM

AB	APOTHECON	**EQ 62.5MG BASE/5ML**	N61455 001

DICLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL

	DYNAPEN				
AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001	>ADD>	
	@	EQ 62.5MG BASE/5ML	N50337 002	>ADD>	
	@ BRISTOL	EQ 62.5MG BASE/5ML	N50337 002		

DIDANOSINE

POWDER FOR RECONSTITUTION; ORAL

	VIDEX				
	BRISTOL MYERS SQUIBB	250MG/PACKET	N20155 005 OCT 09, 1991		
	+	375MG/PACKET	N20155 006 OCT 09, 1991		
	+	250MG/PACKET	N20155 005 OCT 09, 1991		
	@	375MG/PACKET	N20155 006 OCT 09, 1991	>ADD>	

DIENESTROL

CREAM; VAGINAL

	DIENESTROL				
AT	+ JOHNSON RW	0.01%	N06110 005	>ADD>	
	+	0.01%	N06110 005	>ADD>	
	DV			>ADD>	
	@ HOECHST MARION RSSL	0.01%	N83518 001	>ADD>	
AT	MERRELL DOW	0.01%	N83518 001	>ADD>	

DIFLORASONE DIACETATE

CREAM; TOPICAL

	DIFLORASONE DIACETATE				
	@ UPJOHN	0.05%	N19259 001 AUG 28, 1985		
	FLORONE E				
BX	+ UPJOHN	0.05%	N19259 001 AUG 28, 1985		
	PSORCON				
BX	DERMIK	0.05%	N20205 001 NOV 20, 1992		
BX	+	0.05%	N20205 001 NOV 20, 1992		

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARDIZEM CD				
BC	+ CARDERM	300MG	N20062 004 DEC 27, 1991		
	DILACOR XR				
BC	RHONE POULENC RORER	120MG	N20092 001 MAY 29, 1992		
BC	+	120MG	N20092 001 MAY 29, 1992		
BC		180MG	N20092 002 MAY 29, 1992		
BC	+	180MG	N20092 002 MAY 29, 1992		
BC		240MG	N20092 003 MAY 29, 1992		
BC	+	240MG	N20092 003 MAY 29, 1992		
	TIAZAC				
BC	BIOVAIL	120MG	N20401 001 SEP 11, 1995		
BC		180MG	N20401 002 SEP 11, 1995		
BC		240MG	N20401 003 SEP 11, 1995		
BC		300MG	N20401 004 SEP 11, 1995		
	+	360MG	N20401 005 SEP 11, 1995		

INJECTABLE; INJECTION

	CARDIZEM				
	+ HOECHST MARION RSSL	25MG/VIAL	N20027 003 AUG 18, 1995		

TABLET; ORAL

	DILTIAZEM HCL				
AB	LEMMON	30MG	N74185 001 MAY 31, 1995		
AB		60MG	N74185 002 MAY 31, 1995		
AB		90MG	N74185 003 MAY 31, 1995		
AB		120MG	N74185 004 MAY 31, 1995		
AB	ZENITH LABS	30MG	N74168 001 MAR 03, 1995		

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL

AB	ZENITH LABS	60MG	N74168 002 MAR 03, 1995
AB		90MG	N74168 003 MAR 03, 1995
AB		120MG	N74168 004 MAR 03, 1995

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

AP	STERIS	50MG/ML	N83531 001
@		50MG/ML	N83531 001

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+	CONTROLLED THERAP	10MG	N20411 001 MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	WEST WARD PHARM	50MG	N83567 001
@		50MG	N83567 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AKPRO

AT	AKORN	0.1%	N74382 001 SEP 29, 1995

DIPIVEFRIN HCL

AT	BAUSCH AND LOMB	0.1%	N74188 001 MAY 19, 1995

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC

+	LILLY	250MG	N50678 001 JUN 19, 1995

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DEPAKOTE

+	ABBOTT	EQ 125MG BASE	N19680 001 SEP 12, 1989
+		EQ 125MG VALPROIC ACID	N19680 001 SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE

	ABBOTT	EQ 125MG BASE	N18723 003 OCT 26, 1984
		EQ 250MG BASE	N18723 001 MAR 10, 1983
+		EQ 500MG BASE	N18723 002 MAR 10, 1983
		EQ 125MG VALPROIC ACID	N18723 003 OCT 26, 1984
		EQ 250MG VALPROIC ACID	N18723 001 MAR 10, 1983
+		EQ 500MG VALPROIC ACID	N18723 002 MAR 10, 1983

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

AP	ASTRA	EQ 12.5MG BASE/ML	N74098 001 FEB 21, 1995
AP	SANOFI WINTHROP	EQ 12.5MG BASE/ML	N74292 001 FEB 16, 1995

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL IN DEXTROSE 5%

AP	+	ABBOTT	1.6MG/ML	N20542 001 AUG 30, 1995

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		INTROPIN		
AP	+	DUPONT MERCK	**40MG/ML**	**N17395 001**
AP	+		**80MG/ML**	**N17395 002**
AP	+		**160MG/ML**	**N17395 003**
AP	+	FAULDING	**40MG/ML**	N17395 001
AP	+		**80MG/ML**	N17395 002
AP	+		**160MG/ML**	N17395 003

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

> ADD >		DOXIL		
> ADD >	+	SEQUUS PHARM	2MG/ML	N50718 001 NOV 17, 1995
> ADD >		**DOXORUBICIN HCL**		
AP		FUJISAWA	**2MG/ML**	**N63277 001** OCT 26, 1995
AP		GENSIA	**2MG/ML**	**N64140 001** JUL 28, 1995
AP			**200MG/100ML**	**N64140 002** JUL 28, 1995
AP		PHARMACHEMIE (NL)	**2MG/ML**	**N63336 001** FEB 28, 1995
AP			**200MG/100ML**	**N63336 004** FEB 28, 1995

DOXYCYCLINE

CAPSULE; ORAL

		DOXYCYCLINE MONOHYDRATE		
	+	VINTAGE PHARMS	EQ 100MG BASE	N50641 001 DEC 29, 1989
		MONODOX		
		OCLASSEN	EQ 50MG BASE	N50641 002 FEB 10, 1992
	+		EQ 100MG BASE	N50641 001 DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

		DOXYCYCLINE HYCLATE		
AB		HALSEY	**EQ 50MG BASE**	**N62119 002** MAY 24, 1985

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

		DOXYCYCLINE HYCLATE		
AB		HALSEY	**EQ 100MG BASE**	**N62119 001** MAY 24, 1985
	@		EQ 50MG BASE	N62119 002 MAY 24, 1985
	@		EQ 100MG BASE	N62119 001 MAY 24, 1985
AB		PVT FORM	**EQ 50MG BASE**	**N62631 001** JUL 24, 1986
AB			**EQ 100MG BASE**	**N62631 002** JUL 24, 1986
	@		EQ 50MG BASE	N62631 001 JUL 24, 1986
	@		EQ 100MG BASE	N62631 002 JUL 24, 1986

DROPERIDOL

INJECTABLE; INJECTION

		DROPERIDOL		
AP		DUPONT MERCK	**2.5MG/ML**	**N71645 001** APR 07, 1988
AP		FAULDING	**2.5MG/ML**	**N71645 001** APR 07, 1988
AP		SANOFI WINTHROP	**2.5MG/ML**	**N72272 001** AUG 31, 1995

EDETATE DISODIUM

INJECTABLE; INJECTION

		SODIUM VERSENATE		
	+	3M	200MG/ML	N10573 001
	@		200MG/ML	N10573 001

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

		VASERETIC		
		MERCK	5MG;12.5MG	N19221 003 JUL 12, 1995

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION
FLOLAN
+ GLAXO WELLCOME — EQ 0.5MG BASE/VIAL — N20444 001 SEP 20, 1995
+ — EQ 1.5MG BASE/VIAL — N20444 002 SEP 20, 1995

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC
AB FAULDING — 250MG — N50536 001
AB + — 250MG — N50536 001
AB + PARKE DAVIS — 250MG — N62338 001
AB + — 250MG — N62618 001 SEP 25, 1985
@ — 250MG — N62338 001
@ — 250MG — N62618 001 SEP 25, 1985

TABLET, DELAYED RELEASE; ORAL
ROBIMYCIN
AB ROBINS AH — 250MG — N61633 001
@ — 250MG — N61633 001

ERYTHROMYCIN ESTOLATE

DROPS; ORAL
ILOSONE
+ DISTA — EQ 100MG BASE/ML — N61894 003

SUSPENSION/DROPS; ORAL
ILOSONE
+ DISTA — EQ 100MG BASE/ML — N61894 003

ERYTHROMYCIN ETHYLSUCCINATE

DROPS; ORAL
PEDIAMYCIN
+ ROSS LABS — EQ 100MG BASE/2.5ML — N62305 002

SUSPENSION; ORAL
WYAMYCIN E
AB WYETH AYERST — EQ 200MG BASE/5ML — N62123 002

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
WYAMYCIN E
AB WYETH AYERST — EQ 400MG BASE/5ML — N62123 001
@ — EQ 200MG BASE/5ML — N62123 002
@ — EQ 400MG BASE/5ML — N62123 001

SUSPENSION/DROPS; ORAL
PEDIAMYCIN
+ ROSS LABS — EQ 100MG BASE/2.5ML — N62305 002

ERYTHROMYCIN STEARATE

TABLET; ORAL
ETHRIL 250
AB SQUIBB — EQ 250MG BASE — N61605 001
@ — EQ 250MG BASE — N61605 001
ETHRIL 500
AB SQUIBB — EQ 500MG BASE — N61605 002
@ — EQ 500MG BASE — N61605 002

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA
>DLT> BX + 3M — 0.05MG/24HR — N20375 001 DEC 22, 1994
>DLT> BX + — 0.1MG/24HR — N20375 002 DEC 22, 1994
>ADD> BX + BERLEX — 0.05MG/24HR — N20375 001 DEC 22, 1994
>ADD> BX + — 0.1MG/24HR — N20375 002 DEC 22, 1994
VIVELLE
BX — 0.05MG/24HR — N20323 002 OCT 28, 1994
BX — 0.1MG/24HR — N20323 004 OCT 28, 1994
— 0.0375MG/24HR — N20323 001 OCT 28, 1994
— 0.075MG/24HR — N20323 003 OCT 28, 1994
BX + CIBA GEIGY — 0.05MG/24HR — N20323 002 OCT 28, 1994
BX + — 0.1MG/24HR — N20323 004 OCT 28, 1994

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	VIVELLE			
	+ CIBA GEIGY	0.0375MG/24HR	N20323 001	OCT 28, 1994
	+	0.075MG/24HR	N20323 003	OCT 28, 1994

ESTRADIOL VALERATE

INJECTABLE; INJECTION

	DELESTROGEN			
AO	+ SQUIBB	10MG/ML	N09402 002	
	+	10MG/ML	N09402 002	
	ESTRADIOL VALERATE			
AO	STERIS	10MG/ML	N83546 001	
	@	10MG/ML	N83546 001	

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

> ADD >	PREMPHASE 14/14			
> ADD >	+ WYETH AYERST	0.625MG,0.625MG;N/A,5MG	N20527 002	NOV 17, 1995
> ADD >				
> ADD >	PREMPRO 14/14			
> ADD >	+ WYETH AYERST	0.625MG,0.625MG;2.5MG, 2.5MG	N20527 001	NOV 17, 1995
> ADD >				
> ADD >				

ESTRONE

INJECTABLE; INJECTION

	ESTROGENIC SUBSTANCE			
BP	WYETH AYERST	2MG/ML	N83488 001	
BP	+	2MG/ML	N83488 001	
	THEELIN			
BP	+ PARKE DAVIS	2MG/ML	N03977 002	
	@	2MG/ML	N03977 002	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

	ETHAMOLIN			
	+ REED AND CARNRICK	50MG/ML	N19357 001	DEC 22, 1988

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

	ETHAMOLIN			
	+ SPKU	50MG/ML	N19357 001	DEC 22, 1988

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28

	NORQUEST FE			
	@ SEARLE	0.035MG;75MG;1MG	N18926 001	JUL 18, 1986
	@ SYNTEX	0.035MG;75MG;1MG	N18926 001	JUL 18, 1986

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	SEARLE	0.035MG;0.5MG	N17566 001	
AB	SYNTEX	0.035MG;0.5MG	N17566 001	
	NORINYL 1+35 21-DAY			
AB	SEARLE	0.035MG;1MG	N17565 001	
AB	SYNTEX	0.035MG;1MG	N17565 001	
	OVCON-35			
	+ BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N18127 001	
	+ MEAD JOHNSON	0.035MG;0.4MG	N18127 001	
	OVCON-50			
	@ BRISTOL MYERS SQUIBB	0.05MG;1MG	N18128 001	
	+ MEAD JOHNSON	0.05MG;1MG	N18128 001	
	TRI-NORINYL 21-DAY			
	+ SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984
	+ SYNTEX	0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	SEARLE	0.035MG;0.5MG	N17743 001	
AB	SYNTEX	0.035MG;0.5MG	N17743 001	
	NORINYL 1+35 28-DAY			
AB	SEARLE	0.035MG;1MG	N17565 002	
AB	SYNTEX	0.035MG;1MG	N17565 002	
	OVCON-35			
	BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N17716 001	
	MEAD JOHNSON	0.035MG;0.4MG	N17716 001	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

OVCON-50			
BRISTOL MYERS SQUIBB	0.05MG;1MG		N17576 001
MEAD JOHNSON	0.05MG;1MG		N17576 001
TRI-NORINYL 28-DAY			
SEARLE	0.035MG,0.035MG;0.5MG,1MG		N18977 002 APR 13, 1984
SYNTEX	0.035MG,0.035MG;0.5MG,1MG		N18977 002 APR 13, 1984

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL

PARSIDOL			
PARKE DAVIS	10MG		N09078 003
	50MG		N09078 006
	100MG		N09078 008
+	10MG		N09078 003
@	50MG		N09078 006
@	100MG		N09078 008

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE			
AP ABBOTT	20MG/ML		N74320 001 AUG 30, 1995
AP	20MG/ML		N74351 001 AUG 30, 1995
AP BEN VENUE	20MG/ML		N74290 001 JUL 17, 1995
AP GENSIA	20MG/ML		N74510 001 JUN 29, 1995
TOPOSAR			
AP PHARMACIA	20MG/ML		N74166 001 FEB 27, 1995

FENOFIBRATE

CAPSULE; ORAL

LIPIDIL			
+ LABS FOURNIER	100MG		N19304 001 DEC 31, 1993

> ADD >
> ADD >

FENOFIBRATE

CAPSULE; ORAL

LIPIDIL			
@ LABS FOURNIER	100MG		N19304 001 DEC 31, 1993

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL

FENTANYL			
ANESTA	EQ 0.1MG BASE		N20195 007 OCT 30, 1995

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF			
+ APOTHECON	0.1MG		N10060 001
+ SQUIBB	0.1MG		N10060 001

FLUNISOLIDE

SPRAY, METERED; NASAL

NASALIDE			
BX + SYNTEX	0.025MG/INH		N18148 001
NASAREL			
BX + SYNTEX	0.025MG/INH		N20409 001 MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE			
AT + HAMILTON PHARMA CA	0.01%		N12787 004
AT +	0.025%		N12787 002
AT +	0.025%		N12787 005
+	0.2%		N16161 002
SYNALAR			
AT + SYNTEX	0.01%		N12787 004
AT +	0.025%		N12787 002
SYNALAR-HP			
+ SYNTEX	0.2%		N16161 002
SYNEMOL			
AT + SYNTEX	0.025%		N12787 005

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL

		FLUOCINOLONE ACETONIDE		
AT	+	HAMILTON PHARMA CA	0.025%	N13960 001
		SYNALAR		
AT	+	SYNTEX	0.025%	N13960 001

SOLUTION; TOPICAL

		FLUOCINOLONE ACETONIDE		
AT	+	HAMILTON PHARMA CA	0.01%	N15296 001
AT		PHARMADERM	0.01%	N88048 001 DEC 16, 1982
		@	0.01%	N88048 001 DEC 16, 1982
		SYNALAR		
AT	+	SYNTEX	0.01%	N15296 001

FLUOCINONIDE

CREAM; TOPICAL

		FLUOCINONIDE		
AB	+	HAMILTON PHARMA CA	0.05%	N16908 002
		FLUOCINONIDE EMOLLIENT BASE		
AB		HAMILTON PHARMA CA	0.05%	N16908 003
		FLUOCINONIDE EMULSIFIED BASE		
AB		NMC	0.05%	N74204 001 JUN 13, 1995
		LIDEX		
AB	+	SYNTEX	0.05%	N16908 002
		LIDEX-E		
AB		SYNTEX	0.05%	N16908 003

GEL; TOPICAL

		FLUOCINONIDE		
AB	+	HAMILTON PHARMA CA	0.05%	N17373 001
		LIDEX		
AB	+	SYNTEX	0.05%	N17373 001

OINTMENT; TOPICAL

		FLUOCINONIDE		
AB	+	HAMILTON PHARMA CA	0.05%	N16909 002
		LIDEX		
AB	+	SYNTEX	0.05%	N16909 002

SOLUTION; TOPICAL

		FLUOCINONIDE		
AT		FOUGERA	0.05%	N72934 001 FEB 27, 1995

FLUOCINONIDE

SOLUTION; TOPICAL

		FLUOCINONIDE		
AT	+	HAMILTON PHARMA CA	0.05%	N18849 001 APR 06, 1984
		LIDEX		
AT	+	SYNTEX	0.05%	N18849 001 APR 06, 1984

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

		PERMITIL		
AA		SCHERING	5MG/ML	N16008 001
AA	+		5MG/ML	N16008 001

FLURBIPROFEN

TABLET; ORAL

		FLURBIPROFEN		
AB		GENEVA PHARMS	50MG	N74448 001 JUL 28, 1995
AB			100MG	N74448 002 JUL 28, 1995
AB		LEMMON	100MG	N74431 001 MAY 31, 1995
AB		NOVOPHARM	50MG	N74405 002 MAY 24, 1995
AB			100MG	N74405 001 MAY 24, 1995
AB		ZENITH LABS	50MG	N74411 001 MAY 31, 1995
AB			100MG	N74411 002 MAY 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

		FLURBIPROFEN SODIUM		
AT		BAUSCH AND LOMB	0.03%	N74447 001 JAN 04, 1995
		OCUFEN		
AT	+	ALLERGAN	0.03%	N19404 001 DEC 31, 1986

FOSINOPRIL SODIUM

TABLET; ORAL
MONOPRIL

+	BRISTOL MYERS SQUIBB	20MG	N19915 003 MAY 16, 1991	> DLT >	
		20MG	N19915 003 MAY 16, 1991	> ADD >	
+		40MG	N19915 004 MAR 28, 1995	> DLT >	

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE

+	FUJISAWA	25MG/ML	N19961 002 JAN 17, 1991	> ADD >	
+	SOLOPAK	25MG/ML	N19961 002 JAN 17, 1991	> ADD >	

GEMFIBROZIL

CAPSULE; ORAL
GEMFIBROZIL

AB	+ MYLAN	300MG	N73466 001 JAN 25, 1993		
	@	300MG	N73466 001 JAN 25, 1993		
AB	PUREPAC PHARM	300MG	N72929 001 JAN 29, 1993		
	@	300MG	N72929 001 JAN 29, 1993		

LOPID

AB	+ PARKE DAVIS	300MG	N18422 002		
	@	300MG	N18422 002		

TABLET; ORAL
GEMFIBROZIL

AB	CHELSEA LABS	600MG	N74442 001 APR 28, 1995	> ADD >	
AB	INVAMED	600MG	N74615 001 SEP 29, 1995	> ADD >	
AB	MYLAN	600MG	N74452 001 FEB 16, 1995	> ADD >	

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAFAIR

AP	PHARMAFAIR	EQ 40MG BASE/ML	N62493 001 AUG 28, 1985	> DLT >	
	@	EQ 40MG BASE/ML	N62493 001 AUG 28, 1985	> ADD >	

GENTAMICIN

AP	INTL MEDICATION	EQ 1MG BASE/ML	N62325 003 JUN 23, 1982	> DLT >	
AP		EQ 100MG BASE/100ML	N62325 004 JUN 23, 1982	> DLT >	
AP		EQ 40MG BASE/ML	N62325 001 JUN 23, 1982	> DLT >	
	@	EQ 1MG BASE/ML	N62325 003 JUN 23, 1982	> ADD >	
	@	EQ 100MG BASE/100ML	N62325 004 JUN 23, 1982	> ADD >	
	@	EQ 40MG BASE/ML	N62325 001 JUN 23, 1982	> ADD >	

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

AT	ADV REMEDIES	EQ 0.3% BASE	N64093 001 AUG 31, 1995	> ADD >	

OINTMENT; TOPICAL
GENTAMICIN SULFATE

AT	PHARMADERM	EQ 0.1% BASE	N62534 001 OCT 10, 1984	> ADD >	
	@	EQ 0.1% BASE	N62534 001 OCT 10, 1984	> ADD >	

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

AT	ALCON	EQ 0.3% BASE	N62196 001	> ADD >	

GLIMEPIRIDE

TABLET; ORAL
AMARYL

	HOECHST ROUSSEL	1MG	N20496 001 NOV 30, 1995	> ADD >	
		2MG	N20496 002 NOV 30, 1995	> ADD >	
	+	4MG	N20496 003 NOV 30, 1995	> ADD >	

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE			
AB	ALPHAPHARM	5MG	N74438 001	JUN 20, 1995
AB		10MG	N74438 002	JUN 20, 1995
AB	BAKER NORTON	5MG	N74497 001	AUG 31, 1995
AB		10MG	N74497 002	AUG 31, 1995
AB	GENEVA PHARMS	5MG	N74305 001	APR 07, 1995
AB		10MG	N74305 002	APR 07, 1995
AB	INVAMED	5MG	N74542 001	JUN 20, 1995
AB		10MG	N74542 002	JUN 20, 1995
AB	WATSON LABS	5MG	N74223 001	FEB 27, 1995
AB		10MG	N74223 002	FEB 27, 1995

GLYBURIDE

TABLET; ORAL

	GLUBATE			
	@ HOECHST ROUSSEL	1.5MG	N20055 001	APR 17, 1992
	@	3MG	N20055 002	APR 17, 1992
	GLYBURIDE			
AB	NOVOPHARM	1.25MG	N74388 001	AUG 29, 1995
AB		2.5MG	N74388 002	AUG 29, 1995
AB		5MG	N74388 003	AUG 29, 1995
	GLYBURIDE (MICRONIZED)			
AB	HOECHST ROUSSEL	1.5MG	N20055 001	APR 17, 1992
AB		3MG	N20055 002	APR 17, 1992
	GLYNASE			
AB	UPJOHN	1.5MG	N20051 001	MAR 04, 1992

GLYBURIDE

TABLET; ORAL

	GLYNASE			
AB	UPJOHN	3MG	N20051 002	MAR 04, 1992
	MICRONASE			
AB	UPJOHN	1.25MG	N17498 001	MAY 01, 1984
AB		2.5MG	N17498 002	MAY 01, 1984
AB	+	5MG	N17498 003	MAY 01, 1984

GLYCINE

SOLUTION; IRRIGATION

	GLYCINE 1.5% IN PLASTIC CONTAINER			
AT	BAXTER	1.5GM/100ML	N18522 001	FEB 19, 1982
	@	1.5GM/100ML	N18522 001	FEB 19, 1982

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

	KYTRIL			
+	SMITHKLINE BEECHAM	EQ 1MG BASE	N20305 001	MAR 16, 1995

GUANABENZ ACETATE

TABLET; ORAL

	GUANABENZ ACETATE			
AB	ZENITH LABS	EQ 4MG BASE	N74149 001	APR 07, 1995
AB		EQ 8MG BASE	N74149 002	APR 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	GUANFACINE HCL			
AB	WATSON LABS	EQ 1MG BASE	N74145 001	OCT 17, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

		GUANFACINE HCL		
AB		WATSON LABS	**EQ 2MG BASE**	**N74145 002** OCT 17, 1995
		TENEX		
AB		ROBINS AH	**EQ 1MG BASE**	**N19032 001** OCT 27, 1986
AB	+		**EQ 2MG BASE**	**N19032 002** NOV 07, 1988
			EQ 1MG BASE	N19032 001 OCT 27, 1986
	+		EQ 2MG BASE	N19032 002 NOV 07, 1988
	@		3MG	N19032 003 NOV 07, 1988
	@		EQ 3MG BASE	N19032 003 NOV 07, 1988

HALCINONIDE

CREAM; TOPICAL

		HALOG		
AT	+	WESTWOOD SQUIBB	**0.1%**	**N17556 001**
	+		0.1%	N17556 001
		HALOG-E		
AT		WESTWOOD SQUIBB	**0.1%**	**N18234 001**
			0.1%	N18234 001

HALOPERIDOL LACTATE

SOLUTION; ORAL

> ADD >		HALOPERIDOL LACTATE		
> ADD >		UDL	EQ 1MG BASE/ML	N74536 001 NOV 02, 1995
> ADD >				
> ADD >				

HALOPROGIN

SOLUTION; TOPICAL

> DLT >		HALOTEX		
> DLT >	+	WESTWOOD SQUIBB	1%	N16943 001
> DLT >			1%	N16943 001
> ADD >	@			

HEPARIN CALCIUM

INJECTABLE; INJECTION

		CALCIPARINE		
	+	CHOAY	25,000 UNITS/ML	N18237 001
	@	SANOFI WINTHROP	25,000 UNITS/ML	N18237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

		HEPARIN LOCK FLUSH		
AP		SANOFI WINTHROP	**10 UNITS/ML**	**N40082 001** FEB 28, 1995
AP			**100 UNITS/ML**	**N40082 002** FEB 28, 1995
		HEPARIN SODIUM		
AP	+	ABBOTT	**2,500 UNITS/ML**	**N05264 014** APR 07, 1986
	+		2,000 UNITS/ML	N05264 013 APR 07, 1986
AP		ELKINS SINN	**10,000 UNITS/ML**	**N17037 013** APR 07, 1986
AP			**5,000 UNITS/0.5ML**	**N17037 013** APR 07, 1986
AP		MARSAM	**1,000 UNITS/ML**	**N40008 001** OCT 10, 1995
AP		PHARMA SERVE NY	**1,000 UNITS/ML**	**N86129 001**
AP		WYETH AYERST	**2,500 UNITS/ML**	**N17007 007**
AP	+		2,500 UNITS/ML	N17007 007
		HEPARIN SODIUM 1000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER		
AP		MCGAW	**200 UNITS/100ML**	**N19130 001** DEC 31, 1984
	@		200 UNITS/100ML	N19130 001 DEC 31, 1984
		HEPARIN SODIUM 1000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
AP		MCGAW	**200 UNITS/100ML**	**N19042 001** MAR 29, 1985
	@		200 UNITS/100ML	N19042 001 MAR 29, 1985
		HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
AP		ABBOTT	**5,000 UNITS/100ML**	**N18916 006** JAN 31, 1984
			5,000 UNITS/100ML	N18916 006 JAN 31, 1984

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN SODIUM 12500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	MCGAW	**5,000 UNITS/100ML**	**N19802 001**	JUL 20, 1992
@		5,000 UNITS/100ML	N19802 001	JUL 20, 1992
	HEPARIN SODIUM 2000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	**200 UNITS/100ML**	**N19130 003**	DEC 31, 1984
@		200 UNITS/100ML	N19130 003	DEC 31, 1984
	HEPARIN SODIUM 2000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	MCGAW	**200 UNITS/100ML**	**N19042 002**	MAR 29, 1985
@		200 UNITS/100ML	N19042 002	MAR 29, 1985
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	ABBOTT	**5,000 UNITS/100ML**	**N18916 007**	JAN 31, 1984
AP		**10,000 UNITS/100ML**	**N18916 008**	JAN 31, 1984
		5,000 UNITS/100ML	N18916 007	JAN 31, 1984
		10,000 UNITS/100ML	N18916 008	JAN 31, 1984
	HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	MCGAW	**5,000 UNITS/100ML**	**N19802 005**	JUL 20, 1992
AP		**10,000 UNITS/100ML**	**N19802 002**	JUL 20, 1992
@		5,000 UNITS/100ML	N19802 005	JUL 20, 1992
@		10,000 UNITS/100ML	N19802 002	JUL 20, 1992
	HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	MCGAW	5,000 UNITS/100ML	N19802 003	JUL 20, 1992
@		5,000 UNITS/100ML	N19802 003	JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN SODIUM 5000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	**1,000 UNITS/100ML**	**N19130 002**	DEC 31, 1984
@		1,000 UNITS/100ML	N19130 002	DEC 31, 1984
	HEPARIN SODIUM PRESERVATIVE FREE			
AP +	ABBOTT	**2,500 UNITS/ML**	**N05264 014**	APR 07, 1986
+		2,000 UNITS/ML	N05264 013	APR 07, 1986
AP	FUJISAWA	**1,000 UNITS/ML**	**N17029 010**	APR 28, 1986
AP +		**1,000 UNITS/ML**	**N17029 010**	APR 28, 1986
AP	PHARMA SERVE NY	**1,000 UNITS/ML**	**N86129 001**	
AP	STERLING WINTHROP	**10,000 UNITS/ML**	**N89522 001**	MAY 04, 1987
AP +		**10,000 UNITS/ML**	**N89522 001**	MAY 04, 1987
	LIQUAEMIN LOCK FLUSH			
AP	ORGANON	**100 UNITS/ML**	**N00552 007**	
@		100 UNITS/ML	N00552 007	
	LIQUAEMIN SODIUM			
AP	ORGANON	**1,000 UNITS/ML**	**N00552 004**	
AP		**5,000 UNITS/ML**	**N00552 003**	
AP		**10,000 UNITS/ML**	**N00552 005**	
@		1,000 UNITS/ML	N00552 004	
@		5,000 UNITS/ML	N00552 003	
@		10,000 UNITS/ML	N00552 005	

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	DRALZINE			
AA	LEMMON	**25MG**	**N84301 001**	
@		25MG	N84301 001	
	HYDRALAZINE HCL			
AA	HALSEY	**50MG**	**N89222 001**	JAN 22, 1986
@		50MG	N89222 001	JAN 22, 1986

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
APRESOLINE-ESIDRIX
+ CIBA 25MG;15MG N12026 002
@ 25MG;15MG N12026 002

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE
AB ASCOT 50MG N87540 001 FEB 03, 1982
@ 50MG N87540 001 FEB 03, 1982
AB INWOOD LABS 25MG N85067 001
@ 25MG N85067 001

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
HYZAAR
+ MERCK 12.5MG;50MG N20387 001 APR 28, 1995

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE
>DLT> AB ZENITH LABS 15MG;250MG N71458 001 MAR 08, 1988
>DLT> AB 25MG;250MG N71459 001 MAR 08, 1988
>DLT> AB 30MG;500MG N71460 001 MAR 08, 1988
>DLT> AB 50MG;500MG N71461 001 MAR 08, 1988
>ADD> @ 15MG;250MG N71458 001 MAR 08, 1988
>ADD> @ 25MG;250MG N71459 001 MAR 08, 1988
>ADD> @ 30MG;500MG N71460 001 MAR 08, 1988
>ADD> @ 50MG;500MG N71461 001 MAR 08, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL
LOPRESSOR HCT
CIBA 25MG;50MG N18303 001 DEC 31, 1984
25MG;100MG N18303 002 DEC 31, 1984
+ 50MG;100MG N18303 003 DEC 31, 1984
LOPRESSOR HCT 100/25
CIBA 25MG;100MG N18303 002 DEC 31, 1984
LOPRESSOR HCT 100/50
+ CIBA 50MG;100MG N18303 003 DEC 31, 1984
LOPRESSOR HCT 50/25
CIBA 25MG;50MG N18303 001 DEC 31, 1984

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE
AB WARNER CHILCOTT 25MG;80MG N71772 001 JAN 26, 1988
@ 25MG;80MG N71772 001 JAN 26, 1988

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
DYAZIDE
SMITHKLINE BEECHAM 25MG;37.5MG N16042 003 MAR 03, 1994
+ 25MG;37.5MG N16042 003 MAR 03, 1994
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB ZENITH LABS 25MG;50MG N74259 001 MAR 30, 1995

HYDROCORTISONE

CREAM; TOPICAL
FLEXICORT
AT WESTWOOD SQUIBB 0.5% N87136 003 APR 08, 1982

HYDROCORTISONE

CREAM; TOPICAL

	FLEXICORT			
AT	WESTWOOD SQUIBB	1%	**N87136 002**	
			APR 08, 1982	
AT		2.5%	**N87136 001**	
			APR 08, 1982	
	@	0.5%	N87136 003	
			APR 08, 1982	
	@	1%	N87136 002	
			APR 08, 1982	
	@	2.5%	N87136 001	
			APR 08, 1982	
	HYDROCORTISONE			
AT	CLAY PARK	0.5%	**N84970 002**	
AT		1%	**N85026 001**	
	@	0.5%	N84970 002	
	@	1%	N85026 001	

ENEMA; RECTAL

	CORTENEMA		
	+	100MG/60ML	N16199 001
BR	+ SOLVAY	100MG/60ML	N16199 001
	HYDROCORTISONE		
BR	COPLEY PHARM	100MG/60ML	N74171 001
			MAY 27, 1994
	@	100MG/60ML	N74171 001
			MAY 27, 1994

LOTION; TOPICAL

	HYDROCORTISONE		
AT	CLAY PARK	0.5%	**N85662 001**
	@	0.5%	N85662 001

OINTMENT; TOPICAL

	HYDROCORTISONE		
	CLAY PARK	0.5%	N84969 003
	@	0.5%	N84969 003

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		CORTISPORIN		
AT	+	BURROUGHS WELLCOME	10.1MG/ML;EQ 3.5MG BASE/ML; 12,000 UNITS/ML	N50479 001
AT	+	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50479 001

HYDROCORTISONE; UREA

CREAM; TOPICAL

		ALPHADERM		
AT		VIVAN	1%;10%	**N86008 001**
	@		1%;10%	N86008 001
		CALMURID HC		
AT	+	PHARMACIA	1%;10%	**N83947 001**
	@		1%;10%	N83947 001

HYDROCORTISONE ACETATE

AEROSOL; RECTAL

	CORTIFOAM		
	+ REED AND CARNRICK	10%	N17351 001
			FEB 10, 1982
	+ SPKU	10%	N17351 001
			FEB 10, 1982

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL; TOPICAL

	EPIFOAM		
BX	REED AND CARNRICK	1%;1%	N86457 001
BX	SPKU	1%;1%	N86457 001
	PROCTOFOAM HC		
BX	REED AND CARNRICK	1%;1%	N86195 001
BX	SPKU	1%;1%	N86195 001

HYDROCORTISONE BUTYRATE

OINTMENT; TOPICAL

	LOCOID		
	@ YAMANOUCHI	0.1%	N18652 001
			OCT 29, 1982
	+	0.1%	N18652 001
			OCT 29, 1982

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

		DILAUDID-HP		
AP	+	KNOLL PHARM	10MG/ML	**N19034 001**
				JAN 11, 1984

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HCL

AP	STERIS	10MG/ML	N74317 001	AUG 23, 1995

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

> ADD >	AB	GENEVA PHARMS	200MG	N40104 001 NOV 30, 1995
> ADD >	AB	ROYCE LABS	200MG	N40133 001 NOV 30, 1995

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE

	+	AKORN	125MG/ML	N18004 001
	@		125MG/ML	N18004 001

HYDROXYUREA

CAPSULE; ORAL
HYDREA

AB	+	SQUIBB	500MG	N16295 001

HYDROXYUREA

AB		ROXANE	500MG	N74476 001 AUG 18, 1995

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP		PHARMAFAIR	50MG/ML	N88881 001 FEB 14, 1986
	@		50MG/ML	N88881 001 FEB 14, 1986
AP		STERIS	25MG/ML	N87274 001
AP			50MG/ML	N87274 002
	@		25MG/ML	N87274 001
	@		50MG/ML	N87274 002

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL
HYDROXYZINE HCL

AA		BARRE	10MG/5ML	N88785 001 FEB 03, 1988
	@		10MG/5ML	N88785 001 FEB 03, 1988

TABLET; ORAL
HYDROXYZINE HCL

AB		HALSEY	50MG	N89396 001 MAY 02, 1988
	@		50MG	N89396 001 MAY 02, 1988
AB		SIDMAK LABS NJ	100MG	N81054 001 SEP 25, 1995

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S MOTRIN

BX	+	MCNEIL CONS PRODS	100MG/5ML	N19842 001 SEP 19, 1989

PEDIA PROFEN

BX	+	MCNEIL CONS PRODS	100MG/5ML	N19842 001 SEP 19, 1989

SUSPENSION/DROPS; ORAL
MOTRIN

	+	MCNEIL CONS PRODS	40MG/ML	N20476 001 MAY 25, 1995

TABLET; ORAL
IBU-TAB

> DLT >	AB	ALRA	800MG	N71965 001 AUG 11, 1988
> DLT >				
> ADD >	@		800MG	N71965 001 AUG 11, 1988
> ADD >				

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

AB		ZENITH LABS	2.5MG	N74299 001 JUL 27, 1995

INDAPAMIDE

TABLET; ORAL
LOZOL
AB + RHONE POULENC RORER 2.5MG N18538 001 JUL 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DECABID
LILLY EQ 50MG BASE N19693 001 DEC 29, 1989
EQ 75MG BASE N19693 002 DEC 29, 1989
+ EQ 100MG BASE N19693 003 DEC 29, 1989
@ EQ 50MG BASE N19693 001 DEC 29, 1989
@ EQ 75MG BASE N19693 002 DEC 29, 1989
@ EQ 100MG BASE N19693 003 DEC 29, 1989

INULIN

INJECTABLE; INJECTION
INULIN AND SODIUM CHLORIDE
+ CYPROS 100MG/ML N02282 001
+ ISO TEX 100MG/ML N02282 001

IOCETAMIC ACID

TABLET; ORAL
CHOLEBRINE
+ MALLINCKRODT 750MG N17129 001
@ 750MG N17129 001

IOHEXOL

SOLUTION; INJECTION, ORAL
OMNIPAQUE 350
NYCOMED 75.5% N20608 003 OCT 24, 1995

IOHEXOL

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 240
NYCOMED 51.8% N20608 001 OCT 24, 1995

OMNIPAQUE 300
NYCOMED 64.7% N20608 002 OCT 24, 1995

IOPAMIDOL

INJECTABLE; INTRAVASCULAR
ISOVUE-200
@ BRACCO 41% N20327 001 OCT 12, 1994
BRACCO DXS 41% N20327 001 OCT 12, 1994

IOPROMIDE

INJECTABLE; INJECTION
ULTRAVIST
+ BERLEX EQ 150MG IODINE/ML N20220 004 MAY 10, 1995
+ EQ 240MG IODINE/ML N20220 003 MAY 10, 1995
+ EQ 300MG IODINE/ML N20220 002 MAY 10, 1995
+ EQ 370MG IODINE/ML N20220 001 MAY 10, 1995

IOTHALAMATE SODIUM

INJECTABLE; INJECTION
ANGIO-CONRAY
+ MALLINCKRODT 80% N13319 001
@ 80% N13319 001

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION
GLOFIL-125
CYPROS 250-300 uCi/ML N17279 001
ISO TEX 250-300 uCi/ML N17279 001

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST

@	BERLEX	EQ 190MG IODINE/ML	N19580 001	DEC 07, 1989
@		EQ 240MG IODINE/ML	N19580 002	DEC 07, 1989
		EQ 190MG IODINE/ML	N19580 001	DEC 07, 1989
		EQ 240MG IODINE/ML	N19580 002	DEC 07, 1989

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL
ATROVENT

+	BOEHRINGER INGELHEIM	0.021MG/INH	N20393 001	OCT 20, 1995
+		0.042MG/INH	N20394 001	OCT 20, 1995

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL S/F

AN	+ DEY	**1%**	**N89252 001**	SEP 15, 1986
	@	1%	N89252 001	SEP 15, 1986

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE

AN	MARSAM	**99.9%**	**N74393 001**	MAY 12, 1995
AN	RHONE POULENC	**99.9%**	**N74502 001**	JUN 27, 1995

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

BC	REED AND CARNRICK	40MG	N19790 001	SEP 02, 1988

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

BC	SPKU	40MG	N19790 001	SEP 02, 1988

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
IMDUR

@	SCHERING	30MG	N20225 001	AUG 12, 1993
+		60MG	N20225 002	AUG 12, 1993
+		120MG	N20225 003	MAR 30, 1995
@	SCHERING PLOUGH	30MG	N20225 001	AUG 12, 1993
+		60MG	N20225 002	AUG 12, 1993

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN

AP	ELKINS SINN	**EQ 75MG BASE/2ML**	**N62324 001**	
AP		**EQ 500MG BASE/2ML**	**N62324 002**	
AP		**EQ 1GM BASE/3ML**	**N62324 003**	
	@	EQ 75MG BASE/2ML	N62324 001	
	@	EQ 500MG BASE/2ML	N62324 002	
	@	EQ 1GM BASE/3ML	N62324 003	

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

+	WYETH AYERST	100MG	N19816 003	FEB 08, 1995
+		150MG	N19816 002	FEB 08, 1995

LACTULOSE

SOLUTION; ORAL
LACTULOSE
AA HI TECH PHARMA 10GM/15ML N74076 001 JUL 03, 1995

SOLUTION; ORAL, RECTAL
LACTULOSE
AA HI TECH PHARMA 10GM/15ML N74077 001 JUL 03, 1995

> ADD > LAMIVUDINE

> ADD > SOLUTION; ORAL
> ADD > EPIVIR
> ADD > GLAXO WELLCOME 10MG/ML N20596 001 NOV 17, 1995
> ADD >

> ADD > TABLET; ORAL
> ADD > EPIVIR
> ADD > + GLAXO WELLCOME 150MG N20564 001 NOV 17, 1995
> ADD >

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL
PREVACID
TAP HOLDINGS 15MG N20406 001 MAY 10, 1995
+ 30MG N20406 002 MAY 10, 1995

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM
+ CETUS BEN VENUE EQ 200MG BASE/VIAL N40056 001 MAY 23, 1995

WELLCOVORIN
AP BURROUGHS WELLCOME EQ 50MG BASE/VIAL N89465 001 JAN 23, 1989
+ EQ 25MG BASE/VIAL N89833 001 JAN 23, 1989
@ GLAXO WELLCOME EQ 25MG BASE/VIAL N89833 001 JAN 23, 1989

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
WELLCOVORIN
@ GLAXO WELLCOME EQ 50MG BASE/VIAL N89465 001 JAN 23, 1989

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON
TAP HOLDINGS 5MG/ML N20263 001 APR 16, 1993
+ 1MG/0.2ML N19010 001 APR 09, 1985
+ TAP PHARMS 5MG/ML N19010 001 APR 09, 1985

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
AP AKORN 1% N85037 001
AP 2% N85037 002
@ 1% N85037 001
@ 2% N85037 002
AP FUJISAWA 2% N80420 004
@ 2% N80420 004
AP SANOFI WINTHROP 1% N40013 001 JUN 23, 1995
AP 2% N40078 001 JUN 23, 1995

SOLUTION; ORAL
LIDOCAINE HCL
AT HI TECH PHARMA 2% N40014 001 JUL 10, 1995

LINDANE

LOTION; TOPICAL
SCABENE
AT STIEFEL 1% N86769 001
@ 1% N86769 001

LINDANE

SHAMPOO; TOPICAL

		SCABENE		
AT		STIEFEL	**1%**	**N87940 001**
				APR 08, 1983
	@		1%	N87940 001
				APR 08, 1983

LISINOPRIL

TABLET; ORAL

		PRINIVIL		
> ADD >	**AB**	MERCK	**2.5MG**	**N19558 006**
> ADD >				JAN 28, 1994
> DLT >			2.5MG	N19558 006
> DLT >				JAN 28, 1994
		ZESTRIL		
> ADD >	**AB**	ZENECA	**2.5MG**	**N19777 005**
> ADD >				APR 29, 1993
> DLT >		@	2.5MG	N19777 005
> DLT >				APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL

		LITHOTABS		
AB		SOLVAY	**300MG**	**N16980 001**
AB	+		**300MG**	**N16980 001**

TABLET, EXTENDED RELEASE; ORAL

		LITHOBID		
	@	SOLVAY	300MG	N18027 001
			300MG	N18027 001

LOSARTAN POTASSIUM

TABLET; ORAL

		COZAAR		
		MERCK	25MG	N20386 001
				APR 14, 1995
	+		50MG	N20386 002
				APR 14, 1995

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

	PHYSIOLYTE IN PLASTIC CONTAINER		
AT	MCGAW	**30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML**	**N19024 001**
			JUN 08, 1984
		30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19024 001
			JUN 08, 1984
	PHYSIOSOL IN PLASTIC CONTAINER		
AT	ABBOTT	**30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML**	**N17637 002**
			JUL 08, 1982
		30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N17637 002
			JUL 08, 1982
	SYNOVALYTE IN PLASTIC CONTAINER		
AT	BAXTER	**30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML**	**N19326 001**
			JAN 25, 1985
	@	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N19326 001
			JAN 25, 1985

MAGNESIUM SULFATE

INJECTABLE; INJECTION

	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER		
	ABBOTT	1GM/100ML	N20488 001
			JUL 11, 1995
+		2GM/100ML	N20488 002
			JUL 11, 1995

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 10%		
AP	ABBOTT	**10GM/100ML**	**N16269 002**
	@	10GM/100ML	N16269 002
	MANNITOL 15%		
AP	ABBOTT	**15GM/100ML**	**N16269 003**
	@	15GM/100ML	N16269 003
	MANNITOL 20%		
AP	ABBOTT	**20GM/100ML**	**N16269 004**
	@	20GM/100ML	N16269 004

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 25%				
AP	ABBOTT	12.5GM/50ML	N16269 005	> ADD >	
AP		12.5GM/50ML	N16269 006	> ADD	
			AUG 25, 1994		
	@	12.5GM/50ML	N16269 005		
	MANNITOL 5%				
AP	ABBOTT	5GM/100ML	N16269 001		
	@	5GM/100ML	N16269 001		

MASOPROCOL

CREAM; TOPICAL

	ACTINEX				
	+ BLOCK DRUG	10%	N19940 001	> ADD >	
			SEP 04, 1992	> DLT >	
	+ SPKU	10%	N19940 001		
			SEP 04, 1992		

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

	MEBENDAZOLE				
AB	COPLEY PHARM	100MG	N73580 001		
			JAN 04, 1995		
	VERMOX			> ADD >	
AB	+ JANSSEN	100MG	N17481 001	> DLT >	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

	DEPO-PROVERA		
	+ UPJOHN	100MG/ML	N12541 002
	@	100MG/ML	N12541 002

MEGESTROL ACETATE

TABLET; ORAL

	MEGACE		
AB	BRISTOL MYERS SQUIBB	20MG	N16979 001
AB	+	40MG	N16979 002
AB	MEAD JOHNSON	20MG	N16979 001
AB	+	40MG	N16979 002

MEGESTROL ACETATE

TABLET; ORAL

	MEGESTROL ACETATE		
AB	BARR	40MG	N74621 001
			NOV 30, 1995
AB	ROXANE	20MG	N74458 001
			SEP 29, 1995
AB		40MG	N74458 002
			SEP 29, 1995

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

	NORINYL		
	@ SEARLE	0.1MG;2MG	N13625 004
	@ SYNTEX	0.1MG;2MG	N13625 004

TABLET; ORAL-21

	NORINYL 1+50 21-DAY		
AB	SEARLE	0.05MG;1MG	N13625 002
AB	SYNTEX	0.05MG;1MG	N13625 002
	NORINYL 1+80 21-DAY		
	@ SEARLE	0.08MG;1MG	N16724 001
	@ SYNTEX	0.08MG;1MG	N16724 001

TABLET; ORAL-28

	NORINYL 1+50 28-DAY		
AB	SEARLE	0.05MG;1MG	N16659 001
AB	SYNTEX	0.05MG;1MG	N16659 001
	NORINYL 1+80 28-DAY		
	@ SEARLE	0.08MG;1MG	N16725 001
	@ SYNTEX	0.08MG;1MG	N16725 001

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	METAPROTERENOL SULFATE		
AN	BARRE	0.4%	N71855 001
			JUL 14, 1988
AN		0.6%	N71726 001
			JUL 14, 1988
AN	PACO	0.4%	N71855 001
			JUL 14, 1988
AN		0.6%	N71726 001
			JUL 14, 1988

METAPROTERENOL SULFATE

SYRUP; ORAL
ALUPENT

AA		BOEHRINGER INGELHEIM	10MG/5ML	N17571 001
AA	+		10MG/5ML	N17571 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

		BRISTOL MYERS SQUIBB 500MG	N20357 001 DEC 29, 1994
	+	850MG	N20357 002 DEC 29, 1994
		LIPHA 500MG	N20357 001 DEC 29, 1994
	+	850MG	N20357 002 DEC 29, 1994

METHADONE HYDROCHLORIDE

POWDER; FOR RX COMPOUNDING
METHADONE HCL

MALLINCKRODT	50GM/BOT	N06383 002
	100GM/BOT	N06383 003
	500GM/BOT	N06383 004

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	ROXANE	40MG	N74081 001 APR 28, 1995

METHICILLIN SODIUM

INJECTABLE; INJECTION
STAPHCILLIN

@	APOTHECON	EQ 900MG BASE/VIAL	N50117 001
@		EQ 3.6GM BASE/VIAL	N50117 002
@		EQ 5.4GM BASE/VIAL	N50117 003
@	BRISTOL	EQ 900MG BASE/VIAL	N50117 001
@		EQ 3.6GM BASE/VIAL	N50117 002
@		EQ 5.4GM BASE/VIAL	N50117 003

METHOTRIMEPRAZINE

INJECTABLE; INJECTION
LEVOPROME

+	IMMUNEX	20MG/ML	N15865 001
+	LEDERLE	20MG/ML	N15865 001

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP	DUPONT MERCK	50MG/ML	N70691 001 JUN 19, 1987
AP		50MG/ML	N70849 001 JUN 19, 1987
AP	FAULDING	50MG/ML	N70691 001 JUN 19, 1987
AP		50MG/ML	N70849 001 JUN 19, 1987

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE

BP	AKORN	40MG/ML	N86903 001 OCT 20, 1982
BP		80MG/ML	N86903 002 OCT 20, 1982
	@	40MG/ML	N86903 001 OCT 20, 1982
	@	80MG/ML	N86903 002 OCT 20, 1982

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	DUPONT MERCK	EQ 10MG BASE/2ML	N70847 001 NOV 07, 1988
AP		EQ 10MG BASE/2ML	N71291 001 MAR 03, 1989
AP	FAULDING	EQ 10MG BASE/2ML	N70847 001 NOV 07, 1988
AP		EQ 10MG BASE/2ML	N71291 001 MAR 03, 1989

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	INVAMED	EQ 5MG BASE	N74478 001 OCT 05, 1995
AB		EQ 10MG BASE	N74478 002 OCT 05, 1995

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL
LOPRESSOR

	GEIGY	EQ 100MG TARTRATE	N19786 001 DEC 27, 1989
		EQ 200MG TARTRATE	N19786 002 DEC 27, 1989
		EQ 300MG TARTRATE	N19786 003 DEC 27, 1989
+		EQ 400MG TARTRATE	N19786 004 DEC 27, 1989
@		EQ 100MG TARTRATE	N19786 001 DEC 27, 1989
@		EQ 200MG TARTRATE	N19786 002 DEC 27, 1989
@		EQ 300MG TARTRATE	N19786 003 DEC 27, 1989
@		EQ 400MG TARTRATE	N19786 004 DEC 27, 1989

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB	LEMMON	50MG	N74141 001 JAN 31, 1995
AB		100MG	N74141 002 JAN 31, 1995
AB	PAR PHARM	50MG	N74453 001 APR 27, 1995
AB		100MG	N74453 002 APR 27, 1995

METRONIDAZOLE

CAPSULE; ORAL
FLAGYL

+	SEARLE	375MG	N20334 001 MAY 03, 1995

CREAM; TOPICAL
METROCREAM

+	GALDERMA	0.75%	N20531 001 SEP 20, 1995

METYRAPONE

TABLET; ORAL
METOPIRONE

+	CIBA	250MG	N12911 001
@		250MG	N12911 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	NOVOPHARM	150MG	N74377 001 MAY 16, 1995
AB		200MG	N74377 002 MAY 16, 1995
AB		250MG	N74377 003 MAY 16, 1995

MEXITIL

AB	BOEHRINGER INGELHEIM	150MG	N18873 002 DEC 30, 1985
AB		200MG	N18873 003 DEC 30, 1985
AB	+	250MG	N18873 004 DEC 30, 1985

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ABLE	200MG	N73508 001 NOV 19, 1993
AB	NMC	200MG	N73508 001 NOV 19, 1993

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

	AP	CETUS BEN VENUE	**5MG/VIAL**	**N64117 001**	
				APR 19, 1995	
> ADD >	**AP**		**20MG/VIAL**	**N64117 002**	
> ADD >				APR 19, 1995	
> DLT >			20MG/VIAL	N64117 002	
> DLT >				APR 19, 1995	
> ADD >	**AP**	FAULDING	**20MG/VIAL**	**N64106 001**	
> ADD >				NOV 29, 1995	

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
UNIVASC

SPKU	7.5MG	N20312 001	
		APR 19, 1995	
+	15MG	N20312 002	
		APR 19, 1995	

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN

BC	+ PURDUE FREDERICK	15MG	N19516 003	
			SEP 12, 1989	

ORAMORPH SR

BC	ROXANE	15MG	N19977 004
			NOV 23, 1994

MUPIROCIN CALCIUM

OINTMENT; NASAL
BACTROBAN

+	SMITHKLINE BEECHAM	EQ 2% ACID	N50703 001
			SEP 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL
CELLCEPT

+	SYNTEX	250MG	N50722 001
			MAY 03, 1995

NADOLOL

TABLET; ORAL
NADOLOL

> ADD >	**AB**	INVAMED	**20MG**	**N74501 001**	
> ADD >				NOV 09, 1995	
> ADD >	**AB**		**40MG**	**N74501 002**	
> ADD >				NOV 09, 1995	
> ADD >	**AB**		**80MG**	**N74501 003**	
> ADD >				NOV 09, 1995	

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL

+	SEARLE	EQ 0.2MG BASE/INH	N19886 001
			FEB 13, 1990
+	SYNTEX	EQ 0.2MG BASE/INH	N19886 001
			FEB 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

AP	APOTHECON	**EQ 500MG BASE/VIAL**	**N61984 001**
AP		**EQ 500MG BASE/VIAL**	**N62527 001**
			AUG 02, 1984
AP		**EQ 1GM BASE/VIAL**	**N61984 002**
AP		**EQ 1GM BASE/VIAL**	**N62527 002**
			AUG 02, 1984
AP		**EQ 1GM BASE/VIAL**	**N62732 001**
			DEC 23, 1986
AP		**EQ 2GM BASE/VIAL**	**N61984 003**
AP		**EQ 2GM BASE/VIAL**	**N62527 003**
			AUG 02, 1984
AP		**EQ 2GM BASE/VIAL**	**N62732 002**
			DEC 23, 1986
AP		**EQ 4GM BASE/VIAL**	**N61984 005**
AP		**EQ 10GM BASE/VIAL**	**N62527 004**
			AUG 02, 1984

NAFCILLIN SODIUM

AP	APOTHECON	**EQ 500MG BASE/VIAL**	**N61984 001**
AP		**EQ 500MG BASE/VIAL**	**N62527 001**
			AUG 02, 1984
AP		**EQ 1GM BASE/VIAL**	**N61984 002**
AP		**EQ 1GM BASE/VIAL**	**N62527 002**
			AUG 02, 1984

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

AP	APOTHECON	**EQ 1GM BASE/VIAL**	**N62732 001** DEC 23, 1986
AP		**EQ 2GM BASE/VIAL**	**N61984 003**
AP		**EQ 2GM BASE/VIAL**	**N62527 003** AUG 02, 1984
AP		**EQ 2GM BASE/VIAL**	**N62732 002** DEC 23, 1986
AP		**EQ 4GM BASE/VIAL**	**N61984 005**
AP		**EQ 10GM BASE/VIAL**	**N62527 004** AUG 02, 1984

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX

	OHMEDA	EQ 0.1MG BASE/ML	N20459 001 APR 17, 1995
+		EQ 1MG BASE/ML	N20459 002 APR 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP	FUJISAWA	**0.02MG/ML**	**N70648 001** NOV 17, 1986
AP		**0.4MG/ML**	**N70649 001** NOV 17, 1986
@		0.02MG/ML	N70648 001 NOV 17, 1986
@		0.4MG/ML	N70649 001 NOV 17, 1986
AP	MARSAM	**0.4MG/ML**	**N71811 001** JUL 19, 1988
@		0.4MG/ML	N71811 001 JUL 19, 1988

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AQ	AKORN	**100MG/ML**	**N87519 001** SEP 28, 1983

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

@	AKORN	100MG/ML	N87519 001 SEP 28, 1983

NAPROXEN

TABLET; ORAL
NAPROXEN

AB	CHELSEA LABS	**250MG**	**N74457 001** MAY 31, 1995
AB		**375MG**	**N74457 002** MAY 31, 1995
AB		**500MG**	**N74457 003** MAY 31, 1995
AB	DANBURY PHARMA	**250MG**	**N74163 001** FEB 10, 1995
AB		**375MG**	**N74163 002** FEB 10, 1995
AB		**500MG**	**N74163 003** FEB 10, 1995
AB	MOVA	**250MG**	**N74410 001** APR 28, 1995
AB		**375MG**	**N74410 002** APR 28, 1995
AB		**500MG**	**N74410 003** APR 28, 1995
AB	ZENITH LABS	**250MG**	**N74111 001** FEB 28, 1995
AB		**375MG**	**N74111 002** FEB 28, 1995
AB		**500MG**	**N74111 003** FEB 28, 1995

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	CHELSEA LABS	**EQ 250MG BASE**	**N74455 001** MAY 31, 1995
AB		**EQ 500MG BASE**	**N74455 002** MAY 31, 1995
AB	PUREPAC PHARM	**EQ 250MG BASE**	**N74319 001** MAR 20, 1995

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB		PUREPAC PHARM	EQ 500MG BASE	N74319 002 MAR 20, 1995
AB		ZENITH LABS	EQ 250MG BASE	N74230 001 MAR 14, 1995
AB			EQ 500MG BASE	N74230 002 MAR 14, 1995

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

AA		BIOCRAFT	EQ 350MG BASE	N60304 001
			EQ 350MG BASE	N60304 001
AA		LILLY	EQ 350MG BASE	N60385 001
	®		EQ 350MG BASE	N60385 001

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
HABITROL

BC	+	BASEL PHARMS	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991
BC	+	CIBA	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE

	*	MERRELL DOW	EQ 2MG BASE	N18612 001 JAN 13, 1984
	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 001 JAN 13, 1984

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE DS

	*	MERRELL DOW	EQ 4MG BASE	N20066 001 JUN 08, 1992
	+	SMITHKLINE BEECHAM	EQ 4MG BASE	N20066 001 JUN 08, 1992

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
ADALAT CC

BC	+	BAYER	30MG	N20198 001 APR 21, 1993
BC	+		60MG	N20198 002 APR 21, 1993
BC	+		90MG	N20198 003 APR 21, 1993
BC		MILES	30MG	N20198 001 APR 21, 1993
BC			60MG	N20198 002 APR 21, 1993
BC			90MG	N20198 003 APR 21, 1993

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
NISOCOR

	+	BAYER	10MG	N20356 001 FEB 02, 1995
	+		20MG	N20356 002 FEB 02, 1995
	+		30MG	N20356 003 FEB 02, 1995
	+		40MG	N20356 004 FEB 02, 1995
	+	ZENECA	10MG	N20356 001 FEB 02, 1995
	+		20MG	N20356 002 FEB 02, 1995
	+		30MG	N20356 003 FEB 02, 1995
	+		40MG	N20356 004 FEB 02, 1995

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

	NITROFURANTOIN			
AB	GENEVA PHARMS	**25MG**	**N74336 001**	JAN 25, 1995
AB		**50MG**	**N74336 002**	JAN 25, 1995
AB		**100MG**	**N74336 003**	JAN 25, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	NITRO-DUR			
	+ KEY PHARMS	0.1MG/HR	N20145 001	APR 04, 1995
	+	0.2MG/HR	N20145 002	APR 04, 1995
	+	0.3MG/HR	N20145 003	APR 04, 1995
	+	0.4MG/HR	N20145 004	APR 04, 1995
	+	0.6MG/HR	N20145 005	APR 04, 1995
	+	0.8MG/HR	N20145 006	APR 04, 1995

INJECTABLE; INJECTION

	NITROGLYCERIN			
AP	FUJISAWA	**5MG/ML**	**N70077 001**	DEC 13, 1985
	@	5MG/ML	N70077 001	DEC 13, 1985
	NITROSTAT			
AP	PARKE DAVIS	**5MG/ML**	**N18588 002**	DEC 23, 1983
	+	0.8MG/ML	N18588 001	
	@	0.8MG/ML	N18588 001	
	@	5MG/ML	N18588 002	DEC 23, 1983
	TRIDIL			
AP	DUPONT MERCK	**5MG/ML**	**N18537 001**	
	+	0.5MG/ML	N18537 002	JUN 16, 1983
AP	FAULDING	**5MG/ML**	**N18537 001**	
	+	0.5MG/ML	N18537 002	JUN 16, 1983

NORETHINDRONE

TABLET; ORAL

	NOR-Q.D.			
	SEARLE	0.35MG	N17060 001	
	SYNTEX	0.35MG	N17060 001	

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL			
AB	LEMMON	**EQ 10MG BASE**	**N74132 001**	MAR 27, 1995
AB		**EQ 25MG BASE**	**N74132 002**	MAR 27, 1995
AB		**EQ 50MG BASE**	**N74132 003**	MAR 27, 1995
AB		**EQ 75MG BASE**	**N74132 004**	MAR 27, 1995

NYSTATIN

TABLET; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	**500,000 UNITS**	**N60574 001**	
AA	+ SQUIBB	**500,000 UNITS**	**N60574 001**	

TABLET; VAGINAL

	NYSTATIN			
AT	LEMMON	**100,000 UNITS**	**N62502 001**	DEC 23, 1983
	@	100,000 UNITS	N62502 001	DEC 23, 1983

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	PHARMAFAIR	**100,000 UNITS/GM;0.1%**	**N62656 001**	JUL 30, 1986
	@	100,000 UNITS/GM;0.1%	N62656 001	JUL 30, 1986

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA MERCK 10MG N19810 003 OCT 05, 1995

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ZOFRAN IN PLASTIC CONTAINER
+ GLAXO WELLCOME EQ 0.64MG BASE/ML N20403 001 JAN 31, 1995

OXACILLIN SODIUM

CAPSULE; ORAL
OXACILLIN SODIUM
AB APOTHECON **EQ 250MG BASE** **N61450 002**
AB + **EQ 500MG BASE** **N61450 001**
PROSTAPHLIN
AB APOTHECON **EQ 250MG BASE** **N61450 002**
AB + **EQ 500MG BASE** **N61450 001**
@ EQ 500MG BASE N50118 002
@ BRISTOL EQ 500MG BASE N50118 002

POWDER FOR RECONSTITUTION; ORAL
OXACILLIN SODIUM
AA APOTHECON **EQ 250MG BASE/5ML** **N61457 001**
PROSTAPHLIN
AA APOTHECON **EQ 250MG BASE/5ML** **N61457 001**
@ EQ 250MG BASE/5ML N50194 001
@ BRISTOL EQ 250MG BASE/5ML N50194 001

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL
DARICON
+ PFIZER 10MG N11612 001
@ 10MG N11612 001

PENBUTOLOL SULFATE

TABLET; ORAL
LEVATOL
@ REED AND CARNRICK 10MG N18976 001 DEC 30, 1987
+ 20MG N18976 004 JAN 05, 1989
@ SPKU 10MG N18976 001 DEC 30, 1987
+ 20MG N18976 004 JAN 05, 1989

PENICILLAMINE

TABLET; ORAL
DEPEN
+ WALLACE 250MG N19854 001
DEPEN 250
+ WALLACE 250MG N19854 001

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM
@ CONSOLIDATED PHARM 500,000 UNITS/VIAL N60806 001
@ 1,000,000 UNITS/VIAL N60806 002
@ 5,000,000 UNITS/VIAL N60806 003
@ 10,000,000 UNITS/VIAL N60806 004
@ COPANOS 500,000 UNITS/VIAL N60806 001
@ 1,000,000 UNITS/VIAL N60806 002
@ 5,000,000 UNITS/VIAL N60806 003
@ 10,000,000 UNITS/VIAL N60806 004
AP + LILLY **1,000,000 UNITS/VIAL** **N60384 002**
AP + **5,000,000 UNITS/VIAL** **N60384 001**
AP + **20,000,000 UNITS/VIAL** **N60384 005**
AP **20,000,000 UNITS/VIAL** **N60601 001**
+ 200,000 UNITS/VIAL N60384 004
+ 500,000 UNITS/VIAL N60384 003
@ 200,000 UNITS/VIAL N60384 004
@ 500,000 UNITS/VIAL N60384 003
@ 1,000,000 UNITS/VIAL N60384 002
@ 5,000,000 UNITS/VIAL N60384 001
@ 20,000,000 UNITS/VIAL N60384 005
@ 20,000,000 UNITS/VIAL N60601 001
PFIZERPEN
AP PFIZER **1,000,000 UNITS/VIAL** **N60657 001**

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

		PFIZERPEN		
AP	+	PFIZER	1,000,000 UNITS/VIAL	N60657 001
AP			5,000,000 UNITS/VIAL	N60657 002
AP	+		5,000,000 UNITS/VIAL	N60657 002
AP			20,000,000 UNITS/VIAL	N60657 003
AP	+		20,000,000 UNITS/VIAL	N60657 003

TABLET; ORAL

		PENICILLIN G POTASSIUM		
AB		DISTA	250,000 UNITS	N60403 001
	@	LILLY	250,000 UNITS	N60403 001

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

		PENICILLIN G PROCAINE		
	@	CONSOLIDATED PHARM	300,000 UNITS/ML	N60800 001
	@		600,000 UNITS/1.2ML	N60800 002
	@	COPANOS	300,000 UNITS/ML	N60800 001
	@		600,000 UNITS/1.2ML	N60800 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

		PENICILLIN V POTASSIUM		
AA		CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61529 001
AA			EQ 250MG BASE/5ML	N61529 002
AA		COPANOS	EQ 125MG BASE/5ML	N61529 001
AA			EQ 250MG BASE/5ML	N61529 002

TABLET; ORAL

		BETAPEN-VK		
AB		APOTHECON	EQ 250MG BASE	N61411 001
AB			EQ 500MG BASE	N61411 002
		PENICILLIN V POTASSIUM		
> ADD > AB		BIOCHEMIE	EQ 250MG BASE	N64071 001
				NOV 30, 1995
> ADD >				N64071 002
> ADD > AB			EQ 500MG BASE	NOV 30, 1995
> ADD >				N61528 001
AB		CONSOLIDATED PHARM	EQ 250MG BASE	N61528 002
AB			EQ 500MG BASE	N61528 001
AB		COPANOS	EQ 250MG BASE	N61528 002
AB			EQ 500MG BASE	
		VEETIDS		
AB		APOTHECON	EQ 250MG BASE	N61411 001

PENICILLIN V POTASSIUM

TABLET; ORAL

		VEETIDS		
AB		APOTHECON	EQ 500MG BASE	N61411 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

		PENTACARINAT		
AP		ARMOUR	300MG/VIAL	N73447 001 APR 28, 1994
AP		RHONE POULENC RORER	300MG/VIAL	N73447 001 APR 28, 1994
		PENTAMIDINE ISETHIONATE		
AP		STERIS	300MG/VIAL	N74303 001 AUG 17, 1995

PERINDOPRIL ERBUMINE

TABLET; ORAL

		ACEON		
		AMARIC	2MG	N20184 001 DEC 30, 1993
			4MG	N20184 002 DEC 30, 1993
	+		8MG	N20184 003 DEC 30, 1993
		JOHNSON RW	2MG	N20184 001 DEC 30, 1993
			4MG	N20184 002 DEC 30, 1993
	+		8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	MELFIAT-105		
@	NUMARK	105MG	N87487 001 OCT 13, 1982
@	SOLVAY	105MG	N87487 001 OCT 13, 1982
	SPRX-105		
@	NUMARK	105MG	N88024 001 DEC 22, 1982

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
SPRX-105
@ SOLVAY 105MG N88024 001
DEC 22, 1982

TABLET; ORAL
MELFIAT
@ NUMARK 35MG N83790 002
@ SOLVAY 35MG N83790 002
PHENDIMETRAZINE TARTRATE
@ NUMARK 35MG N83790 001
@ SOLVAY 35MG N83790 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL
AA LEMMON **30MG** **N87777 001**
NOV 01, 1985
@ 30MG N87777 001
NOV 01, 1985

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
IONAMIN
FISONS EQ 15MG BASE N11613 004
+ EQ 30MG BASE N11613 002
IONAMIN-15
FISONS EQ 15MG BASE N11613 004
IONAMIN-30
+ FISONS EQ 30MG BASE N11613 002

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC
+ LEO PHARM 12.5MG N19456 001
DEC 28, 1989
+ 25MG N19456 002
DEC 28, 1989
@ 12.5MG N19456 001
DEC 28, 1989

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC
@ LEO PHARM 25MG N19456 002
DEC 28, 1989

PINDOLOL

TABLET; ORAL
PINDOLOL
AB ROYCE LABS **5MG** **N74437 001**
FEB 27, 1995
AB **10MG** **N74437 002**
FEB 27, 1995

PIROXICAM

CAPSULE; ORAL
PIROXICAM
AB ROYCE LABS **10MG** **N74460 001**
SEP 29, 1995
AB **20MG** **N74460 002**
SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

POWDER FOR RECONSTITUTION; ORAL
NULYTELY-FLAVORED
BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT N19797 002
NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
COLYTE
AA KREMERS URBAN **227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT** **N18983 010**
JAN 31, 1989

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	COLYTE			
AA	KREMERS URBAN	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 007	JUN 12, 1987
@	REED AND CARNRICK	120GM/PACKET;1.49GM/PACKET; 3.36GM/PACKET;2.92GM/PACKET; 11.36GM/PACKET	N18983 005	OCT 26, 1984
@		227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N18983 004	OCT 26, 1984
@		360GM/PACKET;4.47GM/PACKET; 10.08GM/PACKET;8.76GM/PACKET; 34.08GM/PACKET	N18983 006	OCT 26, 1984
AA	SPKU	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 010	JAN 31, 1989
AA		240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 007	JUN 12, 1987
@		120GM/PACKET;1.49GM/PACKET; 3.36GM/PACKET;2.92GM/PACKET; 11.36GM/PACKET	N18983 005	OCT 26, 1984
@		227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N18983 004	OCT 26, 1984
@		360GM/PACKET;4.47GM/PACKET; 10.08GM/PACKET;8.76GM/PACKET; 34.08GM/PACKET	N18983 006	OCT 26, 1984
	COLYTE-FLAVORED			
AA	KREMERS URBAN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 008	NOV 14, 1991
AA		240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 009	NOV 14, 1991
AA	SPKU	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 008	NOV 14, 1991

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	COLYTE-FLAVORED			
AA	SPKU	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 009	NOV 14, 1991
	GOLYTELY			
AA	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N19011 002	JUN 02, 1992

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	MINIZIDE			
	PFIZER	0.5MG;1MG	N17986 001	
		0.5MG;2MG	N17986 002	
+		0.5MG;5MG	N17986 003	
		0.5MG;EQ 1MG BASE	N17986 001	
		0.5MG;EQ 2MG BASE	N17986 002	
+		0.5MG;EQ 5MG BASE	N17986 003	

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE			
AP	AKORN	2MEQ/ML	N88286 001	SEP 05, 1985
@		2MEQ/ML	N88286 001	SEP 05, 1985

TABLET, EXTENDED RELEASE; ORAL

	KAON CL			
	SAVAGE LABS	6.7MEQ	N17046 001	
@		6.7MEQ	N17046 001	
	KAON CL-10			
BC	SAVAGE LABS	10MEQ	N17046 002	
@		10MEQ	N17046 002	

PREDNISOLONE

TABLET; ORAL

	CORTALONE		
BX	HALSEY	1MG	N80304 003

PREDNISOLONE

TABLET; ORAL
CORTALONE
BX HALSEY 2.5MG N80304 002
BX 5MG N80304 001
@ 1MG N80304 003
@ 2.5MG N80304 002
@ 5MG N80304 001
PREDNISOLONE
BX SPERTI 1MG N80358 001
1MG N80358 001

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS
AB ALCON **1%** **N17469 001**
BX 1% N17469 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL
AP + MERCK SHARP DOHME **EQ 20MG PHOSPHATE/ML** **N11583 002**
+ EQ 20MG PHOSPHATE/ML N11583 002
PREDNISOLONE SODIUM PHOSPHATE
AP STERIS **EQ 20MG PHOSPHATE/ML** **N80517 001**
@ EQ 20MG PHOSPHATE/ML N80517 001

PREDNISONE

TABLET; ORAL
CORTAN
BX HALSEY 20MG N87480 001
@ 20MG N87480 001

PROBUCOL

TABLET; ORAL
LORELCO
@ HOECHST MARION RSSL 250MG N17535 001
@ 500MG N17535 002
JUL 06, 1988
MERRELL DOW 250MG N17535 001

PROBUCOL

TABLET; ORAL
LORELCO
+ MERRELL DOW 500MG N17535 002
JUL 06, 1988

PROCAINAMIDE HYDROCHLORIDE

TABLET; ORAL
PRONESTYL
APOTHECON 250MG N17371 001
375MG N17371 002
+ 500MG N17371 003
SQUIBB 250MG N17371 001
375MG N17371 002
+ 500MG N17371 003

TABLET, EXTENDED RELEASE; ORAL
PROCAN SR
AB PARKE DAVIS **250MG** **N86468 001**
@ 250MG N86468 001
PRONESTYL-SR
BC APOTHECON 500MG N87361 001
BC BRISTOL MYERS SQUIBB 500MG N87361 001

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL
AP AKORN **25MG/ML** **N83955 002**
AP **50MG/ML** **N83955 001**
@ 25MG/ML N83955 002
@ 50MG/ML N83955 001

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE
AA DANBURY PHARMA **15MG** **N83029 002**
@ 15MG N83029 002
AA GLOBAL PHARMS **15MG** **N84541 002**
@ 15MG N84541 002
AA TABLICAPS **15MG** **N84428 001**
@ 15MG N84428 001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		OPHTHAINE		
AT	+	APOTHECON	0.5%	N08883 001
AT	+	SQUIBB	0.5%	N08883 001
		PROPARACAINE HCL		
AT		BAUSCH AND LOMB	0.5%	N40074 001 SEP 29, 1995

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL		
AB	PARKE DAVIS	20MG	N70439 001 SEP 15, 1986
AB		40MG	N70440 001 SEP 15, 1986
AB		60MG	N70441 001 SEP 24, 1986
AB		80MG	N70442 001 SEP 15, 1986
AB	WARNER CHILCOTT	10MG	N70438 001 SEP 15, 1986
@		10MG	N70438 001 SEP 15, 1986
@		20MG	N70439 001 SEP 15, 1986
@		40MG	N70440 001 SEP 15, 1986
@		60MG	N70441 001 SEP 24, 1986
@		80MG	N70442 001 SEP 15, 1986

PROPYLTHIOURACIL

TABLET; ORAL

	PROPYLTHIOURACIL		
BD	LILLY	50MG	N06213 001
@		50MG	N06213 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	PROTRIPTYLINE HCL		
AB	SIDMAK LABS NJ	5MG	N73644 001 AUG 24, 1995
AB		10MG	N73645 001 AUG 24, 1995
	VIVACTIL		
AB	MERCK SHARP DOHME	5MG	N16012 001
AB	+	10MG	N16012 002

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PYRIDOXINE HCL		
AP	AKORN	100MG/ML	N87967 001 OCT 01, 1982
@		100MG/ML	N87967 001 OCT 01, 1982

QUINESTROL

TABLET; ORAL

	ESTROVIS		
	+ PARKE DAVIS	0.1MG	N16768 002
	@	0.1MG	N16768 002

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

	QUINALAN		
BC	LANNETT	324MG	N88081 001 FEB 10, 1986
@		324MG	N88081 001 FEB 10, 1986

QUINIDINE SULFATE

TABLET; ORAL

	QUINIDINE SULFATE		
AB	PHOENIX LABS NY	200MG	N83963 001
@	VINTAGE PHARMS	200MG	N83963 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL		
AB	PVT FORM	250MG	N62686 001 JUL 24, 1986
AB		500MG	N62686 002 JUL 24, 1986
	@	250MG	N62686 001 JUL 24, 1986
	@	500MG	N62686 002 JUL 24, 1986

FIBER, EXTENDED RELEASE; PERIODONTAL

	ACTISITE		
	+ ON SITE	12.7MG/FIBER	N50653 001 MAR 25, 1994
	+ ON SITE ALZA	12.7MG/FIBER	N50653 001 MAR 25, 1994

OINTMENT; OPHTHALMIC

	ACHROMYCIN		
	+ LEDERLE	10MG/GM	N50266 001
	@ STORZ OPHTHALM	10MG/GM	N50266 001

SUSPENSION; ORAL

	ACHROMYCIN V		
AB	+ LEDERLE	125MG/5ML	N50263 002
	SUMYCIN		
AB	APOTHECON	125MG/5ML	N60400 001
	TETRACYCLINE HCL		
AB	BARRE	125MG/5ML	N60633 001
AB	MK LABS	125MG/5ML	N60174 001
	@ PROTER	125MG/5ML	N60446 001
AB	PUREPAC PHARM	125MG/5ML	N60291 001
	TETRACYN		
AB	PFIPHARMECS	125MG/5ML	N60095 001
	TETRAMED		
AB	ZENITH LABS	125MG/5ML	N61468 001

SUSPENSION/DROPS; OPHTHALMIC

	ACHROMYCIN		
	+ LEDERLE	1%	N50268 001
	@ STORZ OPHTHALM	1%	N50268 001

SYRUP; ORAL

	ACHROMYCIN V		
AB	+ LEDERLE	125MG/5ML	N50263 002
	SUMYCIN		
AB	SQUIBB	125MG/5ML	N60400 001

TETRACYCLINE HYDROCHLORIDE

SYRUP; ORAL

	TETRACYCLINE HCL		
AB	BARRE	125MG/5ML	N60633 001
AB	MK LABS	125MG/5ML	N60174 001
AB	PUREPAC PHARM	125MG/5ML	N60291 001
	TETRACYN		
AB	PFIPHARMECS	125MG/5ML	N60095 001
	TETRAMED		
AB	ZENITH LABS	125MG/5ML	N61468 001

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	THEOPHYLLINE		
BC	FAULDING	100MG	N89976 001 JAN 04, 1995
BC		200MG	N89977 001 JAN 04, 1995
BC		300MG	N89932 001 JAN 04, 1995

TABLET, EXTENDED RELEASE; ORAL

	LABID		
BC	+ PROCTER AND GAMBLE	250MG	N87225 001
	@	250MG	N87225 001
	THEOLAIR-SR		
BC	3M	250MG	N86363 002 JUL 16, 1987
		250MG	N86363 002 JUL 16, 1987
	THEOPHYLLINE		
AB	INWOOD LABS	450MG	N40034 001 APR 28, 1995
	UNI-DUR		
BC	+ KEY PHARMS	400MG	N89822 001 JAN 04, 1995
	+	600MG	N89823 001 JAN 04, 1995
	UNIPHYL		
BC	PURDUE FREDERICK	400MG	N87571 001 SEP 01, 1982

THEOPHYLLINE SODIUM GLYCINATE

TABLET; ORAL
ASBRON
+ DORSEY — EQ 150MG BASE — N85148 001
@ SANDOZ — EQ 150MG BASE — N85148 001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL
AP AKORN — 100MG/ML — N87968 001 OCT 01, 1982
@ — 100MG/ML — N87968 001 OCT 01, 1982

THIOTEPA

INJECTABLE; INJECTION
THIOPLEX
IMMUNEX — 15MG/VIAL — N20058 001 DEC 22, 1994
AP LEDERLE — 15MG/VIAL — N20058 001 DEC 22, 1994

THIOTEPA
AP + IMMUNEX — 15MG/VIAL — N11683 001
+ — 15MG/VIAL — N11683 001

TICARCILLIN DISODIUM

INJECTABLE; INJECTION
TICAR
>DLT< + SMITHKLINE BEECHAM — EQ 6GM BASE/VIAL — N50497 003
>ADD< @ — EQ 6GM BASE/VIAL — N50497 003

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC
BETIMOL
+ LEIRAS — EQ 0.25% BASE — N20439 001 MAR 31, 1995
+ — EQ 0.5% BASE — N20439 002 MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE
AT ALCON — EQ 0.25% BASE — N74261 001 APR 28, 1995
AT — EQ 0.5% BASE — N74262 001 APR 28, 1995

TIMOPTIC
AT + MERCK — EQ 0.25% BASE — N18086 001
AT + — EQ 0.5% BASE — N18086 002

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1
+ BRISTOL MYERS — 6.5% — N19355 001 DEC 30, 1986
+ BRISTOL MYERS SQUIBB — 6.5% — N19355 001 DEC 30, 1986

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL
TONOCARD
ASTRA MERCK — 400MG — N18257 001 NOV 09, 1984
+ — 600MG — N18257 002 NOV 09, 1984
MERCK SHARP DOHME — 400MG — N18257 001 NOV 09, 1984
+ — 600MG — N18257 002 NOV 09, 1984

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
ULTRAM
+ JOHNSON RW — 50MG — N20281 002 MAR 03, 1995
@ — 100MG — N20281 001 MAR 03, 1995

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

	TRAZODONE HCL			
AB	SIDMAK LABS NJ	150MG	N71525 001	MAR 09, 1988
	TRAZON-150			
AB	SIDMAK LABS NJ	150MG	N71525 001	MAR 09, 1988

TRETINOIN

CAPSULE; ORAL

>ADD<	VESANOID			
>ADD<	+ ROCHE	10MG	N20438 001	NOV 22, 1995
>ADD<				
>ADD<				

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	KENALOG-H			
AT	APOTHECON	0.1%	N86240 001	
AT	WESTWOOD SQUIBB	0.1%	N86240 001	

INJECTABLE; INJECTION

	KENALOG-10			
	+ APOTHECON	10MG/ML	N12041 001	
	+ WESTWOOD SQUIBB	10MG/ML	N12041 001	
	KENALOG-40			
BP	APOTHECON	40MG/ML	N14901 001	
BP	WESTWOOD SQUIBB	40MG/ML	N14901 001	

LOTION; TOPICAL

	KENALOG			
AT	APOTHECON	0.025%	N84343 001	
AT	+	0.1%	N84343 002	
	@	0.025%	N11602 003	
	@	0.1%	N11602 001	
AT	WESTWOOD SQUIBB	0.025%	N84343 001	
AT	+	0.1%	N84343 002	
	@	0.025%	N11602 003	
	@	0.1%	N11602 001	
	TRIAMCINOLONE ACETONIDE			
AT	BARRE	0.025%	N87191 001	SEP 08, 1982
	@	0.025%	N87191 001	SEP 08, 1982

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	TRIAMCINOLONE ACETONIDE IN ABSORBASE			
	+ CAROLINA MEDCL	0.05%	N89595 001	MAR 23, 1995

PASTE; DENTAL

	KENALOG IN ORABASE			
AT	+ APOTHECON	0.1%	N12097 001	
AT	+ SQUIBB	0.1%	N12097 001	

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

	ARISTOCORT			
BP	+ LEDERLE	25MG/ML	N11685 003	
	+	25MG/ML	N11685 003	
	TRIAMCINOLONE DIACETATE			
BP	AKORN	25MG/ML	N85122 001	
BP		40MG/ML	N86394 001	
	@	25MG/ML	N85122 001	
	@	40MG/ML	N86394 001	

TRIAZOLAM

TABLET; ORAL

	TRIAZOLAM			
AB	CHELSEA LABS	0.125MG	N74445 001	OCT 20, 1995
AB		0.25MG	N74445 002	OCT 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL

	NAQUA			
BP	SCHERING	2MG	N12265 001	
	@	2MG	N12265 001	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

	TRIFLURIDINE			
AT	STERIS	1%	N74311 001	OCT 06, 1995

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC
VIROPTIC
AT + GLAXO WELLCOME 1% N18299 001

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL
ARTANE
> DLT > AA LEDERLE 2MG/5ML N06773 009
> ADD > AA + 2MG/5ML N06773 009

TRILOSTANE

CAPSULE; ORAL
MODRASTANE
SANOFI WINTHROP 30MG N18719 002
DEC 31, 1984
+ 60MG N18719 001
DEC 31, 1984
@ 30MG N18719 002
DEC 31, 1984
@ 60MG N18719 001
DEC 31, 1984

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL
ASCENT EQ 25MG BASE/5ML N74374 001
JUN 23, 1995

TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
TRIPROLIDINE HCL
+ DANBURY PHARMA 2.5MG N85094 001
@ 2.5MG N85094 001

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL
TERFONYL
+ SQUIBB 167MG/5ML;167MG/5ML; 167MG/5ML N06904 002
@ 167MG/5ML;167MG/5ML; 167MG/5ML N06904 002

TABLET; ORAL
SULFA-TRIPLE #2
AB GLOBAL PHARMS 167MG;167MG;167MG N80079 001
AB + 167MG;167MG;167MG N80079 001
TERFONYL
AB + SQUIBB 167MG;167MG;167MG N06904 001
@ 167MG;167MG;167MG N06904 001

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
AP + APOTHECON 3MG/ML N05657 001
AP + SQUIBB 3MG/ML N05657 001

UROFOLLITROPIN

INJECTABLE; INJECTION
METRODIN
SERONO 150 IU/AMP N19415 003
SEP 18, 1986

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX
+ GLAXO WELLCOME EQ 500MG BASE N20487 001
JUN 23, 1995
@ EQ 1GM BASE N20487 002
JUN 23, 1995

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID
AA HIGH TECH PHARMA 250MG/5ML N74060 001
JAN 13, 1995

VANCOMYCIN HYDROCHLORIDE

POWDER FOR RECONSTITUTION; ORAL

		VANCOCIN HCL		
AA		LILLY	**EQ 250MG BASE/5ML**	**N61667 002** JUL 13, 1983
AA	+		**EQ 500MG BASE/6ML**	**N61667 001**
AB			**EQ 250MG BASE/5ML**	**N61667 002** JUL 13, 1983
	+		EQ 500MG BASE/6ML	N61667 001
		VANCOLED		
AA		LEDERLE	**EQ 250MG BASE/5ML**	**N63321 002** OCT 15, 1993
AA			**EQ 500MG BASE/6ML**	**N63321 003** OCT 15, 1993
AB			**EQ 250MG BASE/5ML**	**N63321 002** OCT 15, 1993
	@		EQ 500MG BASE/6ML	N63321 003 OCT 15, 1993

VECURONIUM BROMIDE

INJECTABLE; INJECTION

		NORCURON		
AP	+	ORGANON	**10MG/VIAL**	**N18776 002** APR 30, 1984
AP	+		**20MG/VIAL**	**N18776 003** JAN 03, 1992
		VECURONIUM BROMIDE		
AP		STERIS	**10MG/VIAL**	**N74334 001** AUG 31, 1995
AP			**20MG/VIAL**	**N74334 002** AUG 31, 1995

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

	VERAPAMIL HCL		
AP	BEDFORD	**2.5MG/ML**	**N72888 001** JUL 28, 1995

VITAMIN A

CAPSULE; ORAL

	VITAMIN A		
AA	BANNER PHARMACAPS	**50,000 USP UNITS**	**N83973 001**

VITAMIN A

CAPSULE; ORAL

	VITAMIN A		
	@ BANNER PHARMACAPS	50,000 USP UNITS	N83973 001

VITAMIN A PALMITATE

CAPSULE; ORAL

	VITAMIN A		
AA	BANNER PHARMACAPS	**EQ 50,000 UNITS BASE**	**N80702 001**
	@	EQ 50,000 UNITS BASE	N80702 001
	VITAMIN A PALMITATE		
AA	BANNER PHARMACAPS	**EQ 50,000 UNITS BASE**	**N83948 001**
	@	EQ 50,000 UNITS BASE	N83948 001

WARFARIN SODIUM

INJECTABLE; INJECTION

	COUMADIN		
	+ DUPONT MERCK	5MG/VIAL	N09218 024 FEB 07, 1995

WATER FOR INJECTION, STERILE

LIQUID; N/A

	BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER		
AP	FUJISAWA	**100%**	**N89099 001** DEC 29, 1987
AP		**100%**	**N89100 001** DEC 29, 1987
	@	100%	N89099 001 DEC 29, 1987
	@	100%	N89100 001 DEC 29, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACETAMINOPHEN			
ABLE	120MG	N73106 001	>ADD<
		FEB 27, 1995	>ADD<
	325MG	N73107 001	
		FEB 27, 1995	
	650MG	N73108 001	
		FEB 27, 1995	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A		
+ CIBA	0.5%;0.05%	N18746 002
		JUL 11, 1994

AVOBENZONE; PADIMATE O

>DLT<	LOTION; TOPICAL		
>DLT<	PHOTOPLEX		
>DLT<	+ ALLERGAN HERBERT	3%;7%	N19459 001
>DLT<			SEP 30, 1988
>ADD<	@	3%;7%	N19459 001
>ADD<			SEP 30, 1988

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL

POLYSPORIN		
@ GLAXO WELLCOME	10,000 UNITS/GM; 2,000,000 UNITS/GM	N50167 002
		MAR 01, 1985

CIMETIDINE

TABLET; ORAL

TAGAMET HB		
+ SMITHKLINE BEECHAM	100MG	N20238 001
		JUN 19, 1995

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE			
PERRIGO	1.34MG	N74512 001	
		NOV 22, 1995	

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

ANTITUSSIVE		
PERRIGO	12.5MG/5ML	N71292 001
		APR 10, 1987
@	12.5MG/5ML	N71292 001
		APR 10, 1987
BELDIN		
HALSEY	12.5MG/5ML	N89179 001
		JUN 05, 1986
@	12.5MG/5ML	N89179 001
		JUN 05, 1986
BENYLIN		
+ PARKE DAVIS	12.5MG/5ML	N06514 004
@	12.5MG/5ML	N06514 004
DIPHEN		
@ MORTON GROVE	12.5MG/5ML	N70118 001
		OCT 01, 1985
PENNEX	12.5MG/5ML	N70118 001
		OCT 01, 1985
DIPHENHYDRAMINE HCL		
CUMBERLAND SWAN	12.5MG/5ML	N73611 001
		AUG 20, 1992
@	12.5MG/5ML	N73611 001
		AUG 20, 1992
HI TECH PHARMA	12.5MG/5ML	N72416 001
		SEP 28, 1990
@	12.5MG/5ML	N72416 001
		SEP 28, 1990
HYDRAMINE		
BARRE	12.5MG/5ML	N70205 001
		JAN 28, 1986
@	12.5MG/5ML	N70205 001
		JAN 28, 1986
SILPHEN		
SILARX	12.5MG/5ML	N72646 001
		FEB 27, 1992
@	12.5MG/5ML	N72646 001
		FEB 27, 1992

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

VICKS FORMULA 44			
@ PROCTER AND GAMBLE	12.5MG/5ML	N70524 001 JAN 14, 1987	
VICKS HLTH CARE	12.5MG/5ML	N70524 001 JAN 14, 1987	

FAMOTIDINE

TABLET; ORAL

PEPCID AC			
+ MERCK	10MG	N20325 001 APR 28, 1995	

IBUPROFEN

CAPSULE; ORAL

MIDOL			
+ WINTHROP	200MG	N70626 001 SEP 02, 1987	
	200MG	N71002 001 SEP 02, 1987	
@	200MG	N70626 001 SEP 02, 1987	
@	200MG	N71002 001 SEP 02, 1987	> DLT > > DLT > > DLT >
PROVEL			
+ SANDOZ	200MG	N20402 001 APR 20, 1995	> ADD > > ADD >

SUSPENSION; ORAL

CHILDREN'S MOTRIN			
+ MCNEIL CONS PRODS	100MG/5ML	N20516 001 JUN 16, 1995	

TABLET; ORAL

MIDOL			
WINTHROP	200MG	N70591 001 SEP 02, 1987	
	200MG	N71001 001 SEP 02, 1987	
@	200MG	N70591 001 SEP 02, 1987	
@	200MG	N71001 001 SEP 02, 1987	

INSULIN PORK

INJECTABLE; INJECTION

INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17926 003
REGULAR INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17926 003

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

VELOSULIN		
NOVO NORDISK	100 UNITS/ML	N18193 001
@	100 UNITS/ML	N18193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)		
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N18195 001
@	30 UNITS/ML;70 UNITS/ML	N18195 001

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R		
+ NOVO NORDISK	100 UNITS/ML	N18778 001 AUG 30, 1983
@	100 UNITS/ML	N18778 001 AUG 30, 1983

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30		
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19585 001 MAR 11, 1988
@	30 UNITS/ML;70 UNITS/ML	N19585 001 MAR 11, 1988
NOVOLIN 70/30		
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19441 001 JUL 11, 1986

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

				>DLT<
INJECTABLE; INJECTION				>DLT<
NOVOLIN 70/30				>DLT<
@ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19441 001		>ADD<
		JUL 11, 1986		

INSULIN SUSP ISOPHANE PURIFIED BEEF

				>DLT<
INJECTABLE; INJECTION				>DLT<
NPH ILETIN II				>DLT<
+ LILLY	100 UNITS/ML	N18479 001		>ADD<
@	100 UNITS/ML	N18479 001		

INSULIN SUSP ISOPHANE PURIFIED PORK

				>DLT<
INJECTABLE; INJECTION				>DLT<
INSULIN INSULATARD NPH NORDISK				>DLT<
+ NOVO NORDISK	100 UNITS/ML	N18194 001		>DLT<
@	100 UNITS/ML	N18194 001		>ADD<
NPH ILETIN II (PORK)				>ADD<
@ LILLY	100 UNITS/ML	N18345 001		
+	100 UNITS/ML	N18345 001		

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION			
INSULATARD NPH HUMAN			
+ NOVO NORDISK	100 UNITS/ML	N19449 001	
		MAY 30, 1986	
@	100 UNITS/ML	N19449 001	
		MAY 30, 1986	

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION				
PROTAMINE ZINC AND ILETIN II				>ADD<
+ LILLY	100 UNITS/ML	N18476 001		>ADD<
@	100 UNITS/ML	N18476 001		
PROTAMINE ZINC INSULIN				
SQUIBB	100 UNITS/ML	N17928 003		
+	100 UNITS/ML	N17928 003		

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION		
ULTRALENTE INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17997 003
@	100 UNITS/ML	N17997 003

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION		
SEMILENTE INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17996 003
@	100 UNITS/ML	N17996 003

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION		
NOVOLIN L		
+ NOVO NORDISK	100 UNITS/ML	N18777 001
		AUG 30, 1983
@	100 UNITS/ML	N18777 001
		AUG 30, 1983

KETOPROFEN

TABLET; ORAL		
ACTRON		
BAYER	12.5MG	N20499 001
		OCT 06, 1995
ORUDIS KT		
+ WHITEHALL ROBINS	12.5MG	N20429 001
		OCT 06, 1995

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL		
LOPERAMIDE HCL		
HI TECH PHARMA	1MG/5ML	N74352 001
		NOV 17, 1995
LEMMON	1MG/5ML	N73478 001
		JUN 23, 1995

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE

LEMMON	2%	N74136 001 JAN 04, 1995

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

ABLE	100MG	N73507 001 NOV 19, 1993
NMC	100MG	N73507 001 NOV 19, 1993

NAPROXEN SODIUM

TABLET; ORAL
ALEVE

HAMILTON PHARMS	EQ 200MG BASE	N20204 002 JAN 11, 1994
+	EQ 200MG BASE	N20204 002 JAN 11, 1994

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
NEOSPORIN

@ GLAXO WELLCOME	EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50176 002 JAN 14, 1985

NONOXYNOL-9

AEROSOL; VAGINAL
DELFEN

@ ORTHO	12.5%	N14349 002

SPONGE; VAGINAL
TODAY

@ WHITEHALL LABS	1GM	N18683 001 APR 01, 1983
@ WHITEHALL ROBINS	1GM	N18683 001 APR 01, 1983

POTASSIUM IODIDE

SOLUTION; ORAL
POTASSIUM IODIDE

+ ROXANE	1GM/ML	N18551 001 FEB 19, 1982
@	1GM/ML	N18551 001 FEB 19, 1982

PYRITHIONE ZINC

LOTION; TOPICAL
HEAD & SHOULDERS CONDITIONER

+ PROCTER AND GAMBLE	0.3%	N19412 002 MAR 10, 1986
@	0.3%	N19412 002 MAR 10, 1986

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 11 / NOV '95

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT 6GM/100ML;0.9GM/100ML N74193
JAN 30, 1995

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January - November, 1995]

NAME **Generic/Chemical** **TN=Trade Name**	**INDICATION DESIGNATED**	**SPONSOR & ADDRESS** **DD=Date Designated** **MA=Marketing Approval**
ADENO-AS'TED VIRAL-BASED VECTOR CYSTIC FIBROSIS GENE THERAPY TN=	TREATMENT OF CYSTIC FIBROSIS.	TARGETED GENETICS CORPORATION 1100 OLIVE WAY, SUITE 100 SEATTLE WA 98101 DD 02/15/95 MA / /
ALGLUCERASE INJECTION TN= CEREDASE	REPLACEMENT THERAPY IN PATIENTS WITH TYPE II AND III GAUCHER'S DISEASE.	GENZYME CORPORATION ONE KENDALL SQUARE CAMBRIDGE MA 02139-1562 DD 07/21/95 MA / /
AMINOCAPROIC ACID TN=	FOR THE TOPICAL TREATMENT OF TRAUMATIC HYPHEMA OF THE EYE.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 01/06/95 MA / /
APL 400-020 TN=	TREATMENT OF CUTANEOUS T CELL LYMPHOMA.	APOLLON, INC. ONE GREAT VALLEY PARKWAY MALVERN PA 19355 DD 03/08/95 MA / /
APOMORPHINE HCL TN=	TREATMENT OF ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	PENTECH PHARMACEUTICALS, INC. 417 HARVESTER COURT WHEELING IL 60090 DD 07/17/95 MA / /
BROMODEOXYURIDINE TN=	RADIATION SENSITIZER IN THE TREATMENT OF PRIMARY BRAIN TUMORS.	NEOPHARM, INC. 225 EAST DEERPATH, SUITE 250 LAKE FOREST IL 60045 DD 09/18/95 MA / /
CHIMERIC A2 (HUMAN-MURINE) IGG MONOCLONAL ANTI-TNF ANTIBODY (CA2) TN=	TREATMENT OF CROHN'S DISEASE.	CENTOCOR, INC 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 DD 11/14/95 MA / /
CHONDROITINASE TN=	TREATMENT OF PATIENTS UNDERGOING VITRECTOMY.	STORZ OPHTHALMICS AMERICAN CYANAMID COMPANY PEARL RIVER NY 10965 DD 02/09/95 MA / /
CLOTRIMIDAZOLE TN=	TREATMENT OF SICKLE CELL DISEASE.	BRUGNARA, CARLO M.D. THE CHILDREN'S HOSPITAL BOSTON MA 02115 DD 04/24/95 MA / /
CYSTIC FIBROSIS TR GENE THERAPY (RECOMBINANT ADENOVIRUS) TN= ADgvCFTR.10	TREATMENT OF CYSTIC FIBROSIS.	GENVAC, INCORPORATED 12111 PARKLAWN DRIVE ROCKVILLE MD 20852 DD 03/09/95 MA / /
ELCATONIN TN=	INTRATHECAL TREATMENT OF INTRACTABLE PAIN.	INNAPHARMA, INCORPORATED 75 MONTEBELLO ROAD SUFFERN NY 10901 DD 09/25/95 MA / /
ENCAPSULATED PORCINE ISLET PREPARATION TN= BETARX	TREATMENT OF TYPE I DIABETIC PATIENTS WHO ARE ALREADY ON IMMUNOSUPPRESSION.	VIVORX 3212 NEBRASKA AVENUE SANTA MONICA CA 90404 DD 07/05/95 MA / /
ETIOCHOLANEDIONE TN=	TREATMENT OF APLASTIC ANEMIA.	SUPERGEN, INC 3158 DES PLAINES AVENUE SUITE 10 DES PLAINES, IL 60018 DD 11/03/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
FIBRINOGEN (HUMAN) TN=	FOR THE CONTROL OF BLEEDING AND PROPHYLACTIC TREATMENT OF PATIENTS DEFICIENT IN FIBRINOGEN.	ALPHA THERAPEUTIC CORPORATION 5555 VALLEY BOULEVARD LOS ANGELES CA 90032 DD 08/23/95 MA / /
FILGRASTIM TN= NEUPOGEN	FOR USE IN THE MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS FOR COLLECTION IN PATIENTS WHO WILL RECEIVE MYELOABLATIVE OR MYELOSUPPRESSIVE CHEMOTHERAPY.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 07/17/95 MA / /
GABAPENTIN TN= NEURONTIN	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	WARNER-LAMBERT COMPANY PARKE-DAVIS PHARMACEUTICAL RESEARCH DIV. ANN ARBOR MI 48105-2430 DD 07/05/95 MA / /
GLUTAMINE TN=	FOR USE WITH HUMAN GROWTH HORMONE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
GLYCERYL TRIOLEATE AND GLYCERYL TRIERUCATE TN= LORENZO'S OIL	TREATMENT OF ADRENOLEUKODYSTROPHY.	MOSER, HUGO W. M.D. JOHNS HOPKINS UNIVERSITY BALTIMORE MD 21205 DD 02/14/95 MA / /
HEPATITIS B IMMUNE GLOBULIN, INTRAVENOUS TN= H-BIGIV	PROPHYLAXIS AGAINST HEPATITIS B VIRUS REINFECTION IN LIVER TRANSPLANT PATIENTS.	NORTH AMERICAN BIOLOGICS, INC. 16500 N.W. 15th AVENUE MIAMI FL 33169 DD 03/08/95 MA / /
HUMAN GROWTH HORMONE TN=	FOR USE WITH GLUTAMINE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
HUMAN IMMUNODEFICIENCY VIRUS IMMUNE GLOBULIN TN= HIVIG	TREATMENT OF HIV-INFECTED PEDIATRIC PATIENTS.	NORTH AMERICAN BIOLOGICALS, INC. 16500 N.W. 15TH AVENUE MIAMI FL 33169 DD 01/04/95 MA / /
INTRAVITREAL GANCICLOVIR FREE ACID IMPLANT TN= VITRASERT IMPLANT	TREATMENT OF CYTOMEGALOVIRUS RETINITIS.	CHIRON VISION 500 IOLAB DRIVE CLAREMONT CA 91711 DD 06/07/95 MA / /
KL4-SURFACTANT TN=	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN ADULTS.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 07/17/95 MA / /
KL4-SURFACTANT TN=	TREATMENT OF RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS.	COCHRANE, CHARLES G. M.D. THE SCRIPPS RESEARCH INSTITUTE 10666 NORTH TORREY PINES ROAD IMM 12 LA JOLLA, CA 92037 DD 10/18/95 MA / /
LAMOTRIGINE TN= LAMICTAL	TREATMENT OF LENNOX-GASTAUT SYNDROME.	BURROUGHS-WELLCOME COMPANY 3030 CORNWALLIS ROAD, P.O. BOX 12700 RESEARCH TRIANGLE PK NC 27709 DD 08/23/95 MA / /
LIDOCAINE PATCH 5% TN=LIDOCAINE PATCH	TREATMENT OF POST-HERPETIC NEURALGIA RESULTING FROM HERPES ZOSTER INFECTIONS.	HIND HEALTH CARE, INC 165 GIBRALTAR COURT SUNNYVALE, CA 94089 DD 10/24/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
MITOLACTOL TN=	AS ADJUVANT THERAPY IN THE TREATMENT OF PRIMARY BRAIN TUMORS.	BIOPHARMACEUTICS, INC. 990 STATION ROAD BELLPORT NY 11713 DD 07/12/95 MA / /
MYCOBACTERIUM AVIUM SENSITIN RS-10 TN=	FOR USE IN THE DIAGNOSIS OF INVASIVE MYCOBACTERIUM AVIUM DISEASE IN IMMUNOCOMPETENT INDIVIDUALS.	STATENS SERUMINSTITUT 5 ARTILLERIVEJ DK-2300 COPENHAGEN S DENMARK DD 10/11/95 MA / /
NITRIC OXIDE TN=	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN ADULTS.	OHMEDA PHARMACEUTICAL PRODUCTS DIVISION 110 ALLEN ROAD LIBERTY CORNER NJ 07938-0804 DD 07/10/95 MA / /
NTBC TN=	TREATMENT OF TYROSINEMIA TYPE 1.	SWEDISH ORPHAN AB ORPHAN PHARMACEUTICAL, USA, INC. NASHVILLE TN 37217 DD 05/16/95 MA / /
OMEGA-3 (N-3) POLYUNSATURATED FATTY ACID WITH ALL DOUBLE BONDS IN THE CIS CONFIGURATION TN=	PREVENTION OF ORGAN GRAFT REJECTION.	RESEARCH TRIANGLE PHARMACEUTICAL 4364 SOUTH ALSTON AVENUE DURHAM, NC 27713 DD 11/22/95 MA / /
PHENYLALANINE AMMONIA-LYASE TN= PHENYLASE	TREATMENT OF HYPERPHENYLALANINEMIA.	IBEX TECHNOLOGIES, INC. 5485 PARE MONTREAL, QUEBEC DD 03/08/95 MA / /
PORFIROMYCIN TN=	TREATMENT OF HEAD AND NECK CANCER.	ONCORX INC. 4 SCIENCE PARK NEW HAVEN CT 06511 DD 09/19/95 MA / /
PURIFIED TYPE II COLLAGEN TN= COLLORAL	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	AUTOIMMUNE, INCORPORATED 128 SPRING STREET LEXINGTON MA 02173 DD 02/09/95 MA / /
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF ACUTE AND CHRONIC RESPIRATORY SYMPTOMS OF BRONCHIECTASIS.	BIOGEN, INCORPORATED 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 03/06/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN=	TREATMENT OF POST-POLIOMYELITIS SYNDROME.	CEPHALON, INC 145 BRANDYWINE PARKWAY WEST CHESTER, PA 19380 DD 10/13/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF GROWTH HORMONE RECEPTOR DEFICIENCY.	PHARMACIA, INC. PO BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF ANTIBODY-MEDIATED GROWTH HORMONE RESISTANCE IN PATIENTS WITH ISOLATED GROWTH HORMONE DEFICIENCY IA.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RECOMBINANT HUMAN RELAXIN TN=	TREATMENT OF PROGRESSIVE SYSTEMIC SCLEROSIS.	CONNECTIVE THERAPEUTICS, INC. 3400 WEST BAYSHORE ROAD PALO ALTO, CA 94303 DD 11/03/95 MA / /

AME
eneric/Chemical
N=Trade Name

RECOMBINANT METHIONYL CELL FACTOR
TN=

RECOMBINANT METHIONYL CELL FACTOR
TN=

RGG0853, E1A LIPID COM
TN=

RIFAPENTINE
TN=

RIFAPENTINE
TN=

SARGRAMOSTIM
TN= LEUKINE

SORIVUDINE
TN= BRAVAVIR

STERILE AEROSOL TALC
TN=

SU-101
TN=

SYNSORB PK
TN=

THALIDOMIDE
TN=

THALIDOMIDE
TN=

HALIDOMIDE
TN= SYNOVIR

	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ONYL HUMAN STEM	FOR USE IN COMBINATION WITH FILGRASTIM TO DECREASE THE NUMBER OF PHERESES REQUIRED TO COLLECT PERIPHERAL BLOOD PROGENITOR CELLS CAPABLE OF PROVIDING RAPID MULTI-LINEAGE HEMATOPOIETIC RECONSTITUTION FOLLOWING MYELOSUPPRESSIVE OR MYELOABLATIVE THERAPY.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 07/05/95 MA / /
ONYL HUMAN STEM	TREATMENT OF PRIMARY BONE MARROW FAILURE.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 11/22/95 MA / /
D COMPLEX	TREATMENT OF ADVANCED OVARIAN CANCER THAT OVEREXPRESSES THE HER-2/neu ONCOGENE.	RGENE THERAPEUTICS, INC. 2170 BUCKTHORNE PLACE, SUITE 230 THE WOODLANDS TX 77380 DD 09/19/95 MA / /
	TREATMENT OF PULMONARY TUBERCULOSIS.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 94137 DD 06/09/95 MA / /
	TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 64137 DD 06/09/95 MA / /
	TO REDUCE NEUTROPENIA AND LEUKOPENIA AND DECREASE THE INCIDENCE OF DEATH DUE TO INFECTION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA.	IMMUNEX CORPORATION 51 UNIVERSITY STREET SEATTLE WA 98101 DD 03/06/95 MA / /
	TREATMENT OF HERPES ZOSTER (SHINGLES) IN IMMUNOCOMPROMISED PATIENTS.	BRISTOL MYERS SQUIBB 5 RESEARCH PARKWAY P.O. BOX 5100 WALLINGFORD, CT 06492 DD 11/09/95 MA / /
ALC	TREATMENT OF MALIGNANT PLEURAL EFFUSION.	BRYAN CORPORATION 4 PLYMPTON STREET WOBURN MA 01801 DD 09/18/95 MA / /
	TREATMENT OF MALIGNANT GLIOMA.	SUGEN, INC. 515 GALVESTON DRIVE REDWOOD CITY CA 94063-4720 DD 05/25/95 MA / /
	TREATMENT OF VEROCYTOTOXOGENIC E. COLI INFECTIONS.	SYNSORB BIOTECH INC. FOURTH FLOOR, 140 4TH AVENUE SW CALGARY, ALBERTA DD 07/17/95 MA / /
	TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN SEVERELY, TERMINALLY IMMUNOCOMPROMISED PATIENTS.	CELGENE CORPORATION P.O. BOX 4914 WARREN NJ 07059 DD 05/01/95 MA / /
	TREATMENT AND PREVENTION OF RECURRENT APHTHOUS ULCERS IN SEVERELY, TERMINALLY IMMUNOCPOMPROMISED PATIENTS.	ANDRULIS RESEARCH CORPORATION 11800 BALTIMORE AVENUE, SUITE 113 BELTSVILLE MD 20705 DD 05/15/95 MA / /
	TREATMENT OF ERYTHEMA NODOSUM LEPROSUM.	CELGENE CORPORATION 7 POWDER HORN DRIVE, PO BOX 4914 WARREN NJ 07059 DD 07/26/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
TRISODIUM CITRATE CONCENTRATION TN= HEMOCITRATE	FOR USE IN LEUKAPHERESIS PROCEDURES.	HEMOTEC MEDICAL PRODUCTS, INC. BOX 19255 JOHNSTON RI 02919 DD 06/15/95 MA / /
TYLOXAPOL TN=	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs 50 NORTH MEDICAL DRIVE, U OF UTAH SALT LAKE CITY UT 84132 DD 03/08/95 MA / /

Approved Orphan Products in 1995

AMIODARONE HCL TN= CORDARONE	FOR THE ACUTE TREATMENT AND PROPHYLAXIS OF LIFE-THREATENING VENTRICULAR TACHYCARDIA OR VENTRICULAR FIBRILLATION.	WYETH-AYERST LABORATORIES P.O. BOX 8299 PHILADELPHIA PA 19101-1245 DD 03/16/94 MA 08/03/95
DEXRAZOXANE TN= ZINECARD	FOR THE PREVENTION OF CARDIOMYOPATHY ASSOCIATED WITH DOXORUBICIN ADMINISTRATION.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 12/17/91 MA 05/26/95
EPOPROSTENOL TN= FLOLAN	LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION IN NEW YORK HEART ASSOCIATION CLASS III AND CLASS IV PATIENTS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 09/25/85 MA 09/20/95
INTERFERON ALPHA-2A TN= ROFERON	TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML).	HOFFMAN-LA ROCHE 340 KINGSLAND STREET NUTLEY, NJ 07110-1199 DD 06/06/89 MA 10/19/95
Rho (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= WinRho SD	TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA.	RH PHARMACEUTICALS, INC. 104 CHANCELLOR MATHESON ROAD WINNIPEG, MANITOBA DD 11/09/93 MA 03/24/95
TRETINOIN TN= VESANOID	INDUCTION OF REMISSION IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA WHO ARE REFRACTORY TO OR UNABLE TO TOLERATE ANTHRACYCLINE BASED CYTOTOXIC CHEMOTHERAPEUTIC REGIMENS.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 10/24/90 MA 11/22/95

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 1995 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
CLOZAPINE *IN VITRO* AND *IN VIVO* INTERIM (TABLET)	NOV 21, 1995	
CORTICOSTEROIDS, DERMATOLOGIC *IN VIVO* (TOPICAL)	JUN 02, 1995	
FLURBIPROFEN (TABLET)	DEC 24, 1992	JUN 08, 1995
NAPROXEN (TABLET)	JUN 12, 1992	JUN 08, 1995
TERFENADINE (TABLET)	JUN 12, 1992	SEP 11, 1995

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 15MG	94 P-0212/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 30MG	94 P-0211/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 60MG	94 P-0210/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE TABLET; ORAL	712.8MG 60MG 32MG	93 P-0484/ CP1	MIKART	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET, CHEWABLE; ORAL	120MG 12MG	94 P-0182/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN HYDROCODONE BITARTRATE TABLET; ORAL	650MG 5MG	95 P-0222/ CP2	MIKART	NEW STRENGTH	APPROVED NOV 21, 1995
ALBUTEROL SULFATE TABLET, CHEWABLE; ORAL	EQ 2MG BASE EQ 4MG BASE	92 P-0335/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ATRACURIUM BESYLATE INJECTABLE; INJECTION	25MG/ML	94 P-0314/ CP1	ABBOTT	NEW STRENGTH	APPROVED MAY 02, 1995
CALCITONIN, SALMON INJECTABLE; INJECTION	100 IU/ML (0.5ML/AMP) 1ML/AMP)	95 P-0080/ CP1	FERRING	NEW STRENGTH	APPROVED AUG 07, 1995
CAPTOPRIL SOLUTION; ORAL	25MG/ML	95 P-0008/ CP1	ROXANE	NEW DOSAGE FORM NEW STRENGTH	APPROVED AUG 07, 1995
FLUOROURACIL GEL; TOPICAL	5%	94 P-0263/ CP1	BRADLEY PHARMS	NEW DOSAGE FORM	APPROVED SEP 12, 1995
IOPAMIDOL INJECTABLE; INJECTION	61% (250ML/CONTAINER) (500ML/CONTAINER)	95 P-0073/ CP1	ABBOTT	NEW STRENGTH	APPROVED AUG 23, 1995
IOPAMIDOL INJECTABLE; INJECTION	76% (250ML/CONTAINER) (500ML/CONTAINER)	95 P-0073/ CP1	ABBOTT	NEW STRENGTH	APPROVED AUG 23, 1995

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (5ML/VIAL)	94 P-0433/ CP2	LEDERLE	NEW DOSAGE FORM	APPROVED AUG 07, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (20ML/VIAL)	94 P-0433/ CP3	LEDERLE	NEW DOSAGE FORM NEW STRENGTH	APPROVED AUG 07, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (35ML/VIAL)	94 P-0433/ CP1	LEDERLE	NEW DOSAGE FORM	APPROVED AUG 07, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (100MG/VIAL)	93 P-0427/ CP3	ABBOTT	NEW DOSAGE FORM	APPROVED JAN 19, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (250MG/VIAL)	93 P-0427/ CP2	ABBOTT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
LORAZEPAM SOLUTION; ORAL	0.5MG/5ML	94 P-0199/ CP1	ROXANE	NEW DOSAGE FORM	APPROVED FEB 07, 1995
MEDROXYPROGESTERONE ACETATE TABLET; ORAL	2MG 4MG 8MG	92 P-0452/ CP1	CARNRICK	NEW STRENGTH	APPROVED AUG 07, 1995
METHYLPREDNISOLONE TABLET, CHEWABLE; ORAL	4MG 16MG 24MG 32MG	94 P-0432/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED AUG 07, 1995
SULFAMETHOXAZOLE; TRIMETHOPRIM TABLET, CHEWABLE; ORAL	200MG 40MG	94 P-0186/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
THIORIDAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0283/ CP1	UDL LABS	NEW STRENGTH	APPROVED JAN 19, 1995

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROMORPHONE HYDROCHLORIDE INJECTABLE; INJECTION	0.2MG/ML (50ML PREFILLED SYRINGE)	95 P-0022/ CP1	ASTRA	NEW INDICATION NEW ROUTE OF ADMINISTRATION NEW STRENGTH	DENIED SEP 07, 1995
MEFLOQUINE HYDROCHLORIDE TABLET; ORAL	275MG	94 P-0329/ CP1	LACASSE	NEW DOSING REGIMEN NEW STRENGTH	DENIED SEP 07, 1995
NICOTINE POLACRILEX LOLLIPOP; ORAL	2MG	93 P-0414/ CP1	SAVAGE	NEW DOSAGE FORM	DENIED MAY 02, 1995
NORETHINDRONE ACETATE TABLET; ORAL	1MG 2.5MG	94 P-0446/ CP1	APOTHECON	NEW INGREDIENT NEW STRENGTH	DENIED SEP 07, 1995
SELEGILINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL	10MG	94 P-0387/ CP1	PHARMAVENE	NEW DOSAGE FORM NEW STRENGTH	DENIED MAY 08, 1995
TERFENADINE TABLET, CHEWABLE; ORAL	60MG	94 P-0119/ CP1	DURA PHARMS	NEW DOSAGE FORM	DENIED AUG 23, 1995

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300

REFERENCES

NEW INDICATION

I-117	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB)
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES

REFERENCES

PATENT USE CODE

U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS

EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-109	USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20482 001	ACARBOSE; PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
>ADD>	20482 002	ACARBOSE; PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
	19872 001	ACETAMINOPHEN; TYLENOL	5004613	JUL 27, 2007			
			4968509	NOV 06, 2007			
	19806 001	ACRIVASTINE; SEMPREX-D	4820522	JUL 27, 2007		NDF	JUN 08, 1997
>ADD>	20059 001	ADENOSINE; ADENOSCAN	4501893	FEB 01, 2003			
	18062 001	ALBUTEROL SULFATE; PROVENTIL	5070877	DEC 10, 2008	U-116	I-126	MAY 18, 1998
	19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	4499108	JUN 08, 2003			
			4353365	APR 24, 1998			
	18702 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4206758	APR 24, 1998			
	18707 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4124707	DEC 12, 1996			
	20560 001	ALENDRONATE SODIUM; FOSAMAX	4124707	DEC 12, 1996			
			5358941	DEC 02, 2012			
	20560 002	ALENDRONATE SODIUM; FOSAMAX	4621077	NOV 04, 2003	U-114	NCE	SEP 29, 2000
			5358941	DEC 02, 2012			
	19353 001	ALFENTANIL HYDROCHLORIDE; ALFENTA	4621077	NOV 04, 2003	U-114	NCE	SEP 29, 2000
	20379 001	ALPROSTADIL; CAVERJECT	4167574	MAY 05, 1999			
	20379 002	ALPROSTADIL; CAVERJECT	4127118	MAR 16, 1997	U-115	NP	JUL 06, 1998
	20377 001	AMIODARONE HYDROCHLORIDE; CORDARONE	4127118	MAR 16, 1997	U-115	NP	JUL 06, 1998
						ODE	AUG 03, 2002
						NDF	AUG 03, 1998
	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	20364 002	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
>ADD>			4572909	AUG 01, 2006		NCE	JUN 25, 1996
>DLT>			4410520	AUG 11, 2003		NCE	JUL 31, 1997
	20364 003	AMLODIPINE BESYLATE; LOTREL	~~4410520~~	~~OCT 18, 2002~~		~~NCE~~	~~JUL 31, 1997~~
			4879303	MAR 25, 2007		NC	MAR 03, 1998
>ADD>			4572909	AUG 01, 2006		NCE	JUN 25, 1996
>DLT>			4410520	AUG 11, 2003		NCE	JUL 31, 1997
	20364 004	AMLODIPINE BESYLATE; LOTREL	~~4410520~~	~~OCT 18, 2002~~		~~NCE~~	~~JUL 31, 1997~~
			4879303	MAR 25, 2007		NC	MAR 03, 1998
>ADD>			4572909	AUG 01, 2006		NCE	JUN 25, 1996
>DLT>			4410520	AUG 11, 2003		NCE	JUL 31, 1997
	19155 001	AMMONIUM LACTATE; LAC-HYDRIN	~~4410520~~	~~OCT 18, 2002~~		~~NCE~~	~~JUL 31, 1997~~
			4105783	JAN 15, 1997			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19402 001	ASTEMIZOLE; HISMANAL	4219559	APR 03, 2000			
	20259 001	ATOVAQUONE; MEPRON	4981874	AUG 15, 2009	U-69		
	20500 001	ATOVAQUONE; MEPRON	5053432	OCT 01, 2008		NCE	NOV 25, 1997
			4981874	AUG 15, 2009	U-69	NDF	FEB 08, 1998
>ADD>	20428 001	AZELAIC ACID; AZELEX				NCE	SEP 13, 2000
>ADD>	19851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	AUG 11, 2003			
>DLT>	~~19851 001~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN~~	~~4410520~~	~~OCT 18, 2002~~			
>ADD>	19851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	AUG 11, 2003			
>DLT>	~~19851 002~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN~~	~~4410520~~	~~OCT 18, 2002~~			
>ADD>	19851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	AUG 11, 2003			
>DLT>	~~19851 003~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN~~	~~4410520~~	~~OCT 18, 2002~~			
>ADD>	19851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	AUG 11, 2003			
>DLT>	~~19851 004~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN~~	~~4410520~~	~~OCT 18, 2002~~			
>ADD>	20033 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
>DLT>	~~20033 001~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT~~	~~4410520~~	~~OCT 18, 2002~~			
>ADD>	20033 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
>DLT>	~~20033 002~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT~~	~~4410520~~	~~OCT 18, 2002~~			
>ADD>	20033 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
>DLT>	~~20033 003~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT~~	~~4410520~~	~~OCT 18, 2002~~			
>ADD>	20033 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
>DLT>	~~20033 004~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT~~	~~4410520~~	~~OCT 18, 2002~~			
	18827 001	BETAMETHASONE DIPROPIONATE; LOTRISONE	4298604	OCT 06, 2000			
	19555 001	BETAMETHASONE DIPROPIONATE; DIPROLENE AF	4489071	DEC 09, 2003			
	19716 001	BETAMETHASONE DIPROPIONATE; DIPROLENE	4775529	MAY 21, 2007			
	20498 001	BICALUTAMIDE; CASODEX				NCE	OCT 04, 2000
	18644 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			
	18644 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18644 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			
>ADD>	18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	4182763	MAY 22, 2000			
>DLT>	~~18731 001~~	~~BUSPIRONE HYDROCHLORIDE; BUSPAR~~	~~4182763~~	~~JAN 08, 1999~~			
>ADD>	18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	4182763	MAY 22, 2000			
>DLT>	~~18731 002~~	~~BUSPIRONE HYDROCHLORIDE; BUSPAR~~	~~4182763~~	~~JAN 08, 1999~~			
	19215 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	JUL 28, 1997			
	19359 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	JUL 28, 1997			
	20313 002	CALCITONIN, SALMON; MIACALCIN				NDF	AUG 17, 1998
	18343 001	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 002	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 003	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 005	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 006	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18709 001	CAPTOPRIL; CAPOZIDE 25/15	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 002	CAPTOPRIL; CAPOZIDE 25/25	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 003	CAPTOPRIL; CAPOZIDE 50/25	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 004	CAPTOPRIL; CAPOZIDE 50/15	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	19856 001	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
			4832957	JUN 16, 2006			
	19856 002	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
			4832957	JUN 16, 2006			
	20297 001	CARVEDILOL; COREG				NCE	SEP 14, 2000
	20297 002	CARVEDILOL; COREG				NCE	SEP 14, 2000
	20297 003	CARVEDILOL; COREG				NCE	SEP 14, 2000
	20044 001	CETYL ALCOHOL; EXOSURF NEONATAL	5110806	MAY 02, 2006			
>ADD>			4312860	AUG 20, 2003			
>DLT>			~~4312860~~	~~NOV 21, 2001~~			
	18663 001	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18663 002	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			
	20238 001	CIMETIDINE; TAGAMET HB				NS	JUN 19, 1998
						I-137	NOV 15, 1998
>ADD>	19847 001	CIPROFLOXACIN; CIPRO	4670444	DEC 09, 2003			
	19857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4670444	DEC 09, 2003			
	19858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4670444	DEC 09, 2003			
	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
			4670444	DEC 09, 2003	U-36		
	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
			4670444	DEC 09, 2003	U-36		
	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
			4670444	DEC 09, 2003	U-36		
	20398 001	CISAPRIDE MONOHYDRATE; PROPULSID				NCE	JUL 29, 1998
	18891 001	CLONIDINE; CATAPRES-TTS-1	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
	18891 002	CLONIDINE; CATAPRES-TTS-2	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
	18891 003	CLONIDINE; CATAPRES-TTS-3	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
	20222 001	COLESTIPOL HYDROCHLORIDE; COLESTID				NDF	JUL 19, 1997
	12142 006	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 007	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 008	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 009	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 010	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	20287 001	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2000		NCE	DEC 22, 1999
	19849 001	DAPIPRAZOLE HYDROCHLORIDE; REV-EYES	4252721	FEB 07, 2003			
	20071 001	DESOGESTREL; DESOGEN	3927046	NOV 06, 1996			
	20071 002	DESOGESTREL; DESOGEN	3927046	NOV 06, 1996			
	20301 001	DESOGESTREL; ORTHO-CEPT	3927046	NOV 06, 1996			
	20301 002	DESOGESTREL; ORTHO-CEPT	3927046	NOV 06, 1996			
	20212 001	DEXRAZOXANE HYDROCHLORIDE; ZINECARD				NCE	MAY 26, 2000
						ODE	MAY 26, 2002
	20212 002	DEXRAZOXANE HYDROCHLORIDE; ZINECARD				NCE	MAY 26, 2000
						ODE	MAY 26, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5470584	MAY 20, 2011			
>ADD>			5439689	AUG 08, 2012	U-107		
			5286497	MAY 20, 2011			
>ADD>	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5470584	MAY 20, 2011			
>ADD>			5439689	AUG 08, 2012	U-107		
			5286497	MAY 20, 2011			
>ADD>	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5470584	MAY 20, 2011			
>ADD>			5439689	AUG 08, 2012	U-107		
			5286497	MAY 20, 2011			
>ADD>	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5470584	MAY 20, 2011			
>ADD>			5439689	AUG 08, 2012	U-107		
			5286497	MAY 20, 2011			
	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-133	OCT 15, 1995
	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-133	OCT 15, 1995
	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-133	OCT 15, 1995
						NS	SEP 11, 1998
>ADD>	20401 005	DILTIAZEM HYDROCHLORIDE; TIAZAC	5269321	DEC 14, 2010	U-110		
	20411 001	DINOPROSTONE; CERVIDIL	4931288	JAN 16, 2007		NDF	MAR 30, 1998
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008		I-132	MAY 26, 1998
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008		I-132	MAY 26, 1998
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008		I-132	MAY 26, 1998
	20408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413	DEC 12, 2004	U-103	NCE	DEC 09, 1999
			4619939	OCT 28, 2003	U-104		
	19946 001	DOXACURIUM CHLORIDE; NUROMAX				I-121	DEC 08, 1997
	19668 001	DOXAZOSIN MESYLATE; CARDURA	4188390	OCT 18, 2000		I-96	FEB 06, 1998
	19668 002	DOXAZOSIN MESYLATE; CARDURA	4188390	OCT 18, 2000		I-96	FEB 06, 1998
	19668 003	DOXAZOSIN MESYLATE; CARDURA	4188390	OCT 18, 2000		I-96	FEB 06, 1998
	19668 004	DOXAZOSIN MESYLATE; CARDURA	4188390	OCT 18, 2000		I-96	FEB 06, 1998
	20126 001	DOXEPIN HYDROCHLORIDE; ZONALON	4395420	DEC 09, 2001	U-95		
	19221 003	ENALAPRIL MALEATE; VASERETIC	4472380	SEP 18, 2001			
			4374829	FEB 22, 2000		NS	JUL 12, 1998
	19616 004	ENOXACIN; PENETREX	4442101	FEB 04, 2002			
	19616 005	ENOXACIN; PENETREX	4442101	FEB 04, 2002			
	20164 001	ENOXAPARIN SODIUM; LOVENOX				I-118	MAR 09, 1998
	20444 001	EPOPROSTENOL SODIUM; FLOLAN				NCE	SEP 20, 2000
	20444 002	EPOPROSTENOL SODIUM; FLOLAN				NCE	SEP 20, 2000
	18418 001	ERGOLOID MESYLATES; HYDERGINE	4138565	MAY 26, 1996			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18706 001	ERGOLOID MESYLATES; HYDERGINE LC	4366145	JUN 24, 2001			
	19081 002	ESTRADIOL; ESTRADERM	4379454	FEB 17, 2001			
	19081 003	ESTRADIOL; ESTRADERM	4379454	FEB 17, 2001			
	20323 001	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20323 002	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20323 003	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20323 004	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20375 001	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
	20375 002	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
	86069 001	ESTRADIOL; ESTRACE	4436738	MAR 15, 2002			
	20303 001	ESTROGENS, CONJUGATED; PREMPRO (PREMARIN;CYCRIN 14/14)	4826831	MAY 02, 2006	U-102	NP	DEC 30, 1997
>ADD>	20527 001	ESTROGENS, CONJUGATED; PREMPRO 14/14	4826831	MAY 02, 2006	U-102		
	18977 001	ETHINYL ESTRADIOL; TRI-NORINYL 21-DAY	4390531	AUG 10, 2001			
	18977 002	ETHINYL ESTRADIOL; TRI-NORINYL 28-DAY	4390531	AUG 10, 2001			
	18985 001	ETHINYL ESTRADIOL; ORTHO-NOVUM 7/7/7-21	4628051	SEP 26, 2003			
			4616006	SEP 26, 2003			
			4544554	SEP 26, 2003			
			4530839	SEP 26, 2003			
	18985 002	ETHINYL ESTRADIOL; ORTHO-NOVUM 7/7/7-28	4628051	SEP 26, 2003			
			4616006	SEP 26, 2003			
			4544554	SEP 26, 2003			
			4530839	SEP 26, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19697 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003			
		4544554	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
19697 002	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003			
		4544554	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
19462 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
19462 002	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
19510 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
19527 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
20249 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
20325 001	FAMOTIDINE; PEPCID AC	4283408	OCT 15, 2000		NS	APR 28, 1998
20189 001	FELBAMATE; FELBATOL	5082861	SEP 26, 2009	U-83		
		4978680	SEP 26, 2009	U-83		
20189 002	FELBAMATE; FELBATOL	5082861	SEP 26, 2009	U-83		
		4978680	SEP 26, 2009	U-83		
20189 003	FELBAMATE; FELBATOL	5082861	SEP 26, 2009	U-83		
		4978680	SEP 26, 2009	U-83		
19834 001	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
		4264611	JUN 19, 2001	U-3	NCE	JUL 25, 1996
19834 002	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
		4264611	JUN 19, 2001	U-3	NCE	JUL 25, 1996
19834 004	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
		4264611	JUN 19, 2001	U-3	NCE	JUL 25, 1996
19813 001	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19813 002	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19813 003	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19813 004	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19960 001	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19960 002	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19960 003	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19960 004	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19949 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19949 002	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
			4404216	JAN 29, 2004			
	19949 003	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
			4404216	JAN 29, 2004			
	19950 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
			4404216	JAN 29, 2004			
	20090 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
			4404216	JAN 29, 2004			
	20090 002	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
			4404216	JAN 29, 2004			
	20322 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
			4404216	JAN 29, 2004			
	20073 001	FLUMAZENIL; ROMAZICON	4316839	OCT 10, 2004			
	18148 001	FLUNISOLIDE; NASALIDE	4933168	JUN 12, 2007			
	18340 001	FLUNISOLIDE; AEROBID	4933168	JUN 12, 2007			
	20409 001	FLUNISOLIDE; NASAREL	4983595	MAY 22, 2006			
			4933168	JUN 12, 2007			
			4782047	MAY 22, 2006			
	19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTHE/FS				I-122	FEB 16, 1998
>ADD>	19957 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	NOV 14, 2003			
>DLT>	~~19957 001~~	~~FLUTICASONE PROPIONATE; CUTIVATE~~	~~4335121~~	~~MAR 15, 2002~~			
>ADD>	19958 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	NOV 14, 2003			
>DLT>	~~19958 001~~	~~FLUTICASONE PROPIONATE; CUTIVATE~~	~~4335121~~	~~MAR 15, 2002~~			
>ADD>	20121 001	FLUTICASONE PROPIONATE; FLONASE	4335121	NOV 14, 2003		NCE	DEC 14, 1995
>DLT>	~~20121 001~~	~~FLUTICASONE PROPIONATE; FLONASE~~	~~4335121~~	~~MAR 15, 2002~~		~~NCE~~	~~DEC 14, 1995~~
						NDF	OCT 19, 1997
	20261 001	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
	20261 002	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4339445	JUL 29, 1997	U-64	I-127	JUN 16, 1998
	19915 002	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000		I-92	MAY 02, 1998
			4337201	DEC 04, 2002			
	19915 003	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000		I-92	MAY 02, 1998
			4337201	DEC 04, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19915 004	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000		I-92	MAY 02, 1998
			4337201	DEC 04, 2002		NCE	MAY 16, 1996
	20286 001	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000			
			4337201	DEC 04, 2002			
	20286 002	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000			
			4337201	DEC 04, 2002			
	20235 001	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
	20235 002	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
	20235 003	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	5362475	NOV 08, 2011			
	20460 001	GANCICLOVIR; CYTOVENE	4507305	OCT 19, 1999	U-64	NDF	DEC 22, 1997
			4355032	JUN 23, 2003	U-64		
	19661 001	GANCICLOVIR SODIUM; CYTOVENE	4507305	MAY 21, 2001	U-35		
			4423050	MAY 21, 2001	U-34		
			4355032	JUN 23, 2003	U-64		
>ADD>	20496 001	GLIMEPIRIDE; AMARYL				NCE	NOV 30, 2000
>ADD>	20496 002	GLIMEPIRIDE; AMARYL				NCE	NOV 30, 2000
>ADD>	20496 003	GLIMEPIRIDE; AMARYL				NCE	NOV 30, 2000
	20329 001	GLIPIZIDE; GLUCOTROL XL	5091190	JUN 18, 2008	U-111		
			5082668	SEP 16, 2003			
			5024843	SEP 05, 2009			
			4612008	SEP 16, 2003			
			4327725	NOV 25, 2000		NDF	APR 26, 1997
	20329 002	GLIPIZIDE; GLUCOTROL XL	5091190	JUN 18, 2008	U-111		
			5082668	SEP 16, 2003			
			5024843	SEP 05, 2009			
			4612008	SEP 16, 2003			
			4327725	NOV 25, 2000		NDF	APR 26, 1997
	19726 001	GOSERELIN ACETATE; ZOLADEX	4100274	APR 22, 1999			
	20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 12, 2006	U-105	NCE	DEC 29, 1998
						NDF	MAR 16, 1998
	19059 001	HYDROCHLOROTHIAZIDE; INDERIDE LA 80/50	4138475	SEP 14, 1997			
	19059 002	HYDROCHLOROTHIAZIDE; INDERIDE LA 120/50	4138475	SEP 14, 1997			
	19059 003	HYDROCHLOROTHIAZIDE; INDERIDE LA 160/50	4138475	SEP 14, 1997			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19129 001	HYDROCHLOROTHIAZIDE; MAXZIDE	4444769	JUL 27, 2002			
19129 003	HYDROCHLOROTHIAZIDE; MAXZIDE-25	4444769	JUL 27, 2002			
20387 001	HYDROCHLOROTHIAZIDE; HYZAAR	5153197	OCT 06, 2009	U-3	NC	APR 28, 1998
		5138069	AUG 11, 2009		NCE	APR 14, 2000
19842 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		I-123	MAR 24, 1998
20135 001	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
		5215755	JUN 01, 2010		NDF	NOV 16, 1997
20135 002	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
		5215755	JUN 01, 2010		NDF	NOV 16, 1997
20418 001	IBUPROFEN; MOTRIN				I-123	MAR 24, 1998
20516 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
18185 001	INDOMETHACIN; INDOCIN SR	4173626	DEC 11, 1998			
20084 001	IOBENGUANE SULFATE I 131; IOBENGUANE SULFATE I 131				ODE	MAR 25, 2001
18956 007	IOHEXOL; OMNIPAQUE 70	4396597	JUL 14, 1998			
		4250113	DEC 26, 1999			
18735 001	IOPAMIDOL; ISOVUE-M 200	4001323	NOV 24, 1997			
18735 002	IOPAMIDOL; ISOVUE-300	4001323	NOV 24, 1997			
18735 003	IOPAMIDOL; ISOVUE-370	4001323	NOV 24, 1997		D-28	MAY 15, 1998
18735 004	IOPAMIDOL; ISOVUE-M 300	4001323	NOV 24, 1997			
18735 007	IOPAMIDOL; ISOVUE-250	4001323	NOV 24, 1997			
20327 001	IOPAMIDOL; ISOVUE-200	4001323	NOV 24, 1997			
20327 002	IOPAMIDOL; ISOVUE-250	4001323	NOV 24, 1997			
20327 003	IOPAMIDOL; ISOVUE-300	4001323	NOV 24, 1997			
20327 004	IOPAMIDOL; ISOVUE-370	4001323	NOV 24, 1997			
20220 001	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
20220 002	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
20220 003	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
20220 004	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
19710 005	IOVERSOL; OPTIRAY 350				I-131	JUN 21, 1998
18905 002	IOXAGLATE MEGLUMINE; HEXABRIX	4014986	MAY 20, 1997			
20393 001	IPRATROPIUM BROMIDE; ATROVENT				NDF	OCT 20, 1998
20394 001	IPRATROPIUM BROMIDE; ATROVENT				NDF	OCT 20, 1998
20225 003	ISOSORBIDE MONONITRATE; IMDUR				NDF	AUG 12, 1996
					NCE	DEC 30, 1996
20336 001	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
20336 002	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
20083 001	ITRACONAZOLE; SPORANOX	4267179	JUN 23, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19816 002	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	19816 003	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	JUL 14, 1998	U-55		
	19698 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	JUL 14, 1998	U-55	NR	DEC 07, 1997
	19698 002	KETOROLAC TROMETHAMINE; TORADOL	4089969	JUL 14, 1998	U-55	NR	DEC 07, 1997
	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4454151	MAR 22, 2002	U-75		
			4089969	JUL 14, 1998	U-55		
	18686 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4328213	NOV 28, 1999			
>ADD>	20564 001	LAMIVUDINE; EPIVIR				NCE	NOV 17, 2000
>ADD>	20596 001	LAMIVUDINE; EPIVIR				NCE	NOV 17, 2000
	20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20406 001	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
			5045321	SEP 03, 2008			
			5026560	JUN 25, 2008			
			4689333	JUL 29, 2005			
			4628098	JUL 29, 2005		NCE	MAY 10, 2000
	20406 002	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
			5045321	SEP 03, 2008			
			5026560	JUN 25, 2008			
			4689333	JUL 29, 2005			
			4628098	JUL 29, 2005		NCE	MAY 10, 2000
	19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
			4005063	JAN 25, 1996		I-119	MAR 30, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20263 001	LEUPROLIDE ACETATE; LUPRON	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
20263 005	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4849228	JUL 18, 2006			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
		4005063	JAN 25, 1996			
20263 006	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4849228	JUL 18, 2006			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
		4005063	JAN 25, 1996			
18027 001	LITHIUM CARBONATE; LITHOBID	4264573	MAY 21, 1999			
20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	FEB 21, 2006	U-36		
19658 001	LORATADINE; CLARITIN	4282233	JUN 19, 2002	U-77	I-136	SEP 20, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19670 001	LORATADINE; CLARITIN-D	4282233	JUN 19, 2002		NCE	APR 12, 1998
20386 001	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009		NCE	APR 14, 2000
20386 002	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009		NCE	APR 14, 2000
19643 002	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-117	FEB 08, 1998
19643 003	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-117	FEB 08, 1998
19643 004	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-117	FEB 08, 1998
19940 001	MASOPROCOL; ACTINEX	4695590	SEP 04, 2006		NCE	SEP 04, 1997
19591 001	MEFLOQUINE HYDROCHLORIDE; LARIAM	4579855	OCT 01, 2004			
20207 001	MELPHALAN HYDROCHLORIDE; ALKERAN	4997651	NOV 18, 2008			
19884 001	MESNA; MESNEX	4220660	MAR 06, 2001			
19600 001	METHOXSALEN; OXSORALEN-ULTRA	4454152	DEC 21, 2001			
18029 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN-SR	4137300	AUG 20, 1996			
19962 001	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
		5001161	MAR 19, 2008			
		4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
19962 002	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
		5001161	MAR 19, 2008			
		4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
19962 003	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
		5001161	MAR 19, 2008			
		4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
20531 001	METRONIDAZOLE; METROCREAM				NDF	SEP 20, 1998
18654 001	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
18654 002	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
19268 001	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
19268 003	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	FEB 24, 2007		NCE	APR 19, 2000
20312 002	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	FEB 24, 2007		NCE	APR 19, 2000
19625 001	MOMETASONE FUROATE; ELOCON	4808610	OCT 02, 2006			
19796 001	MOMETASONE FUROATE; ELOCON	4775529	MAY 21, 2007			
20459 001	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
20459 002	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
18932 001	NALTREXONE HYDROCHLORIDE; REVIA				I-129	DEC 30, 1997
20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
	20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
	20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
	20152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
	19488 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	FEB 15, 1996			
	19488 002	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	FEB 15, 1996			
	19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	5164405	NOV 17, 2009			
			4880823	NOV 14, 2006			
			3985758	FEB 15, 1996			
	20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
			3985758	FEB 15, 1996			
	20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
			3985758	FEB 15, 1996			
	20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
			3985758	FEB 15, 1996			
	20076 001	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
	20076 002	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
	20076 003	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
	20150 001	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
	20150 002	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
	20150 003	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
>ADD>	20165 001	NICOTINE; NICODERM	5462745	JUN 14, 2008			
			5364630	JUN 14, 2008			
			5344656	JUN 14, 2008			
			5342623	JUN 14, 2008			
			5004610	JUN 14, 2008			
>ADD>	20165 002	NICOTINE; NICODERM	5462745	JUN 14, 2008			
			5364630	JUN 14, 2008			
			5344656	JUN 14, 2008			
			5342623	JUN 14, 2008			
			5004610	JUN 14, 2008			
>ADD>	20165 003	NICOTINE; NICODERM	5462745	JUN 14, 2008			
			5364630	JUN 14, 2008			
			5344656	JUN 14, 2008			
			5342623	JUN 14, 2008			
			5004610	JUN 14, 2008			
	19684 001	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19684 002	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
19684 003	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
20198 001	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
		4892741	JUN 08, 2008			
20198 002	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
		4892741	JUN 08, 2008			
20198 003	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
		4892741	JUN 08, 2008			
20356 001	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20356 002	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20356 003	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20356 004	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20064 001	NITROFURANTOIN; MACROBID	4798725	JUN 16, 2006			
		4772473	JUN 16, 2006			
20145 001	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 002	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 003	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 004	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 005	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 006	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
19508 001	NIZATIDINE; AXID	4375547	APR 12, 2002			
19508 002	NIZATIDINE; AXID	4375547	APR 12, 2002			
19384 002	NORFLOXACIN; NOROXIN	4639458	JAN 22, 2005			
		4146719	FEB 16, 2000			
19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 14, 2003			
		4146719	FEB 16, 2000			
19667 001	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19667 002	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19667 003	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19667 004	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19667 005	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19735 001	OFLOXACIN; FLOXIN	4382892	SEP 02, 2003			
19735 002	OFLOXACIN; FLOXIN	4382892	SEP 02, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19735 003	OFLOXACIN; FLOXIN	4382892	SEP 02, 2003			
20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
20087 002	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
20087 003	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
19810 001	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108		
		4786505	APR 20, 2007	U-108	I-130	JUN 22, 1998
		4255431	APR 05, 2001	U-108		
19810 003	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108		
		4786505	APR 20, 2007	U-108		
		4255431	APR 05, 2001	U-108		
20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005		D-20	FEB 02, 1996
20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-27	APR 10, 1998
		4695578	JAN 25, 2005		NCE	JAN 04, 1996
					I-9	APR 19, 1998
20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-27	APR 10, 1998
		4695578	JAN 25, 2005		NCE	JAN 04, 1996
					I-9	APR 19, 1998
20403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-20	FEB 02, 1996
		4695578	JAN 25, 2005		NCE	JAN 04, 1996
					I-9	AUG 13, 1996
19828 001	OXICONAZOLE NITRATE; OXISTAT	4124767	DEC 27, 1996			
20209 001	OXICONAZOLE NITRATE; OXISTAT	4124767	DEC 27, 1996			
20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005		I-135	SEP 01, 1998
20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005		I-135	SEP 01, 1998
20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005		I-135	SEP 01, 1998
20031 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
20031 002	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
20031 003	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
20031 004	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
20031 005	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
19385 001	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
		4166182	FEB 08, 2000			
19385 002	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
		4166182	FEB 08, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19385 003	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
		4166182	FEB 08, 2000			
17850 001	POTASSIUM CHLORIDE; KLOTRIX	4140756	JUN 10, 1996			
18238 001	POTASSIUM CHLORIDE; MICRO-K	4259315	JUN 13, 2000			
18238 002	POTASSIUM CHLORIDE; MICRO-K 10	4259315	JUN 13, 2000			
19561 003	POTASSIUM CHLORIDE; MICRO-K LS	4259315	JUN 13, 2000			
19898 002	PRAVASTATIN SODIUM; PRAVACHOL	4346227	OCT 20, 2005			
19898 003	PRAVASTATIN SODIUM; PRAVACHOL	4346227	OCT 20, 2005			
19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	OCT 20, 2005			
19775 001	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4327725	NOV 25, 2000			
19775 002	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4327725	NOV 25, 2000			
19627 001	PROPOFOL; DIPRIVAN	4798846	MAR 19, 1997			
		4056635	MAR 19, 1997			
18553 001	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
18553 002	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
18553 003	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
18553 004	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
19536 001	PROPRANOLOL HYDROCHLORIDE; INDERAL	4600708	JUL 19, 2005			
19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	4929605	OCT 07, 2007	U-81		
		4254129	APR 10, 1999	U-81		
20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24	4801461	MAR 14, 2006			
19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		4344949	AUG 17, 2001	U-3		
19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		4344949	AUG 17, 2001	U-3		
19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		4344949	AUG 17, 2001	U-3		
19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		4344949	AUG 17, 2001	U-3		
19901 001	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
19901 002	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
19901 003	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
19901 004	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4880636	MAY 13, 2008			
		4128658	JUL 25, 1997		I-120	MAR 29, 1998
18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4880636	MAY 13, 2008			
		4128658	JUL 25, 1997		I-120	MAR 29, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19090 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
		4128658	JUL 25, 1997			
19593 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4128658	JUL 25, 1997			
19593 002	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	APR 29, 2003			
		4521431	JUN 04, 2002			
		4128658	JUL 25, 1997			
19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004		I-120	MAR 29, 1998
		4128658	JUL 25, 1997			
20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	FEB 22, 2010		I-120	MAR 29, 1998
		4128658	JUL 25, 1997			
20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	FEB 22, 2010		I-120	MAR 29, 1998
		4128658	JUL 25, 1997			
20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009		I-120	MAR 29, 1998
		4128658	JUL 25, 1997			
20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009		I-120	MAR 29, 1998
		4128658	JUL 25, 1997			
20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	APR 13, 2008			
20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	APR 13, 2008			
20236 001	SALMETEROL XINAFOATE; SEREVENT	5380922	MAY 14, 2013			
19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
		4962128	NOV 02, 2009	U-12		
19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
		4962128	NOV 02, 2009	U-12		
19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
		4962128	NOV 02, 2009	U-12		
19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
		4962128	NOV 02, 2009	U-12		
20478 001	SEVOFLURANE; ULTANE				NCE	JUN 07, 2000
19766 001	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
19766 002	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
19766 003	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
19766 004	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
19721 001	SOMATROPIN, BIOSYNTHETIC; NORDITROPIN				NS	MAY 08, 1998
19721 002	SOMATROPIN, BIOSYNTHETIC; NORDITROPIN				NS	MAY 08, 1998
20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U-72		
20132 001	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U-72		
		4816470	DEC 28, 2006	U-72		
20132 002	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U-72		
		4816470	DEC 28, 2006	U-72		
20132 003	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U-72		
		4816470	DEC 28, 2006	U-72		
20070 001	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
		4631286	OCT 25, 2004	U-97		
20070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
		4631286	OCT 25, 2004	U-97		
20070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
		4631286	OCT 25, 2004	U-97		
20070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
		4631286	OCT 25, 2004	U-97		
19829 001	TECHNETIUM TC-99M EXAMETAZIME KIT; CERETEC	4789736	DEC 06, 2005		I-124	APR 07, 1998
		4615876	OCT 07, 2003			
19981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG	4755375	JUL 05, 2005	U-51		
19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997	U-3		
19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997	U-3		
19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997	U-3		
19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
20347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
20347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
18949 001	TERFENADINE; SELDANE	4254129	APR 10, 1999	U-81		
20489 001	TESTOSTERONE; ANDRODERM				NS	SEP 29, 1998
19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
20439 001	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
20439 002	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
20136 001	TORSEMIDE; DEMADEX	RE34672	AUG 11, 2006			
20136 002	TORSEMIDE; DEMADEX	RE34672	AUG 11, 2006			
20136 003	TORSEMIDE; DEMADEX	RE34672	AUG 11, 2006			
20136 004	TORSEMIDE; DEMADEX	RE34672	AUG 11, 2006			
20137 002	TORSEMIDE; DEMADEX	4861786	JUL 08, 2007			
		RE34672	AUG 11, 2006			
20281 001	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
20281 002	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
		4215104	MAR 26, 1999			
18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
		4215104	MAR 26, 1999			
19798 001	TRIAMCINOLONE ACETONIDE; NASACORT	4767612	JAN 23, 2007	U-85		
20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	MAY 20, 2006	U-91		
		4376858	OCT 31, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	SEP 18, 2007		NE	JUN 23, 1998
20487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	SEP 18, 2007		NE	JUN 23, 1998
18776 002	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
		4237126	AUG 20, 1999			
18776 003	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
		4237126	AUG 20, 1999			
20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
19614 001	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
19614 002	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
19614 003	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
20388 001	VINORELBINE TARTRATE; NAVELBINE	4307100	AUG 20, 1999		NCE	DEC 23, 1999
19655 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
19910 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
19951 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
19908 001	ZOLPIDEM TARTRATE; AMBIEN	4382938	OCT 21, 2006	U-74		
19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	OCT 21, 2006	U-74		

*U.S. Government Printing Office: 1996 - 404-907/20005

New 16th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7809

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $72.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (10/95)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Approved drug products with therapeutic equivalence